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Tryptophan (Trp), the amino acid precursor to serotonin, is a common ingredient in many 
commercial equine calming supplements. However, there is little scientific research to support the 
efficacy of tryptophan at modifying horse behavior. The objective of this study was to examine 
how various doses of tryptophan supplementation impacted reactive behavior and physiological 
stress measurements in the horse. Eleven horses (9 geldings, 2 mares) were given four 
treatments—0 mg Trp/kg bodyweight (CON), 20 mg Trp/kg bodyweight (LOW), 40 mg Trp/kg 
bodyweight (MED), and 60 mg Trp/kg bodyweight (HIGH)—in a randomized crossover design. 
Each treatment lasted three days. On Days 1 and 3 of each treatment, horses underwent a behavior 
test to measure startle response. Heart rate measurements and the speed at which the horses fled 
from startling stimuli were recorded. In addition, serum glucose, lactate, and cortisol levels were 
analyzed both immediately before the startle test and again 15 minutes after the test. Significant 
sedative effects were seen at LOW Day 1 on heart rate increase during the startle test (P = 0.05) 
and on change in serum lactate levels (P = 0.03). At MED Day 1, sedative effects were seen on 
change in serum cortisol levels (P = 0.01). Some excitatory effects were seen at MED Day 3 on 
the time for heart rate to return to baseline after the startle test (P = 0.03). No significant effects 
were seen at HIGH Day 1 or Day 3. A subset of blood samples was analyzed for serum free Trp 
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CHAPTER I: LITERATURE REVIEW 
INTRODUCTION 
 This review will begin by covering some of the biochemical properties and pathways of 
tryptophan. We will discuss the physiology of the blood-brain barrier and how tryptophan is 
transported into the central nervous system. From here, we will delve into serotonin biosynthesis 
and metabolism in the brain. We’ll cover some of the physiology and effects this neurotransmitter 
has on the body, particularly on mood. Finally, we’ll review the research on supplemental 
tryptophan in humans and animals, focusing primarily on the horse. The purpose of this literature 
review is to provide a general understanding of the biochemistry, neurophysiology, and research 
that creates the platform which the experiment described in Chapter II is based upon. 
TRYPTOPHAN 
 L-Tryptophan (Trp; L-α-aminoindole-3-propionic acid) is the least abundant amino acid 
found in tissues and food, occurring in approximately 1.4% of protein (Fernstrom and Wurtman, 
1974; Voet and Voet, 1995). Tryptophan was first isolated from casein in 1902 (Yao et al., 2011). 
It is a nonpolar compound with an indole group and is the largest essential amino acid, with a 
molar mass of 204.225 g/mol. The carboxyl group on tryptophan has a pKa value of 2.46 and the 
amine group has a pKa of 9.41. (Voet and Voet, 1995) Only plants and microorganisms have the 
enzymes necessary to synthesize tryptophan, making it one of the essential amino acids for 
monogastric animals and young ruminants, before weaning (Yao et al., 2011).  
The reactions in tryptophan synthesis are shown in Figures 1.1 and 1.2. Aromatic amino 
acid synthesis begins with the same steps: phosphoenolpyruvate (a glycolytic pathway 
intermediate) and erythrose-4-phosphate (a pentose phosphate pathway intermediate) combine and 
undergo seven enzyme-catalyzed reactions. The resulting compound, chorismate, can be utilized 
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to form tryptophan, tyrosine, or phenylalanine. In the biosynthesis of tryptophan, four more 
enzyme-catalyzed reactions take place to yield indole-3-glycerol phosphate. The last two steps 
require tryptophan synthase. The alpha unit of this enzyme first cleaves the compound into indole 
and glyceraldehyde-3-phosphate. The indole is then channeled through a tunnel in the enzyme to 
the beta subunit, where it is joined with serine to form tryptophan. The channeling step of 
tryptophan synthase is unique and important because it prevents the nonpolar indole intermediate 
from escaping the cell via diffusion and from being degraded (Voet and Voet, 1995). 
 Understanding the pathways of tryptophan degradation (shown in Figure 1.3) and their 
products is important in identifying how tryptophan is being metabolized and what it is being used 
for in the body. There are a few notable products of tryptophan degradation. Kynurenine is one 
such intermediate in tryptophan degradation. It is further degraded in several steps to yield alanine, 
which may go on to yield pyruvate. One of these steps is catalyzed by kynureninase, an enzyme 
dependent upon pyridoxal 5’-phosphate (PLP), the active form of vitamin B6. This is notable 
because, while many reactions involving amino acids are PLP-dependent, the cofactor usually 
cleaves different bonds than the ones broken in this reaction. PLP is also necessary in tryptophan 
biosynthesis and it will be an important cofactor in reactions to be discussed later. Quinolinate, 
which is an NAD+ and NADP+ precursor in the liver and kidneys, is another tryptophan metabolite. 
An alternative degradation pathway concludes with reactions identical to those seen in the 
breakdown of lysine; acetoacetate is the final metabolite (Voet and Voet, 1995). 
THE BLOOD-BRAIN BARRIER 
While water, carbon dioxide, oxygen, and lipid-soluble compounds pass through plasma 
membranes and equate between the blood and brain easily, the blood-brain barrier is almost 
impermeable to larger compounds like plasma proteins. However, there are some areas of the 
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brain—parts of the hypothalamus, pineal gland, and medulla—where compounds diffuse more 
easily (Guyton and Hall, 2000). Sites of the blood-brain barrier include the arachnoid membrane, 
the blood vessels in the subarachnoid space, and the choroid plexus. The arachnoid villus is shown 
in Figure 1.4. When pressure of the cerebrospinal fluid exceeds that of the sinus blood, the 
arachnoid villi will open, allowing the bulk movement of metabolic and waste molecules from the 
CSF into venous sinus blood (Rapoport, 1976). Unlike other capillaries in the body, those found 
in the brain are connected by tight junctions and, as shown in Figure 1.5, glial cells cover about 
85% of the vessel surface (Rapoport, 1976). This serves as a second site of the blood-brain barrier. 
The choroid plexus is the third site of the blood-brain barrier and is shown in Figure 1.6. The 
choroid plexus secretes cerebrospinal fluid and is located in the lateral, third, and fourth ventricles 
(Rapoport, 1976). 
Tryptophan, like some other amino acids, binds non-covalently to serum albumin (Yao et 
al., 2011). Actually, most (80-90%) of circulating tryptophan is bound to albumin (Bosch et al., 
2007). Several studies provide evidence that increasing free tryptophan relates to a greater ability 
of the amino acid to pass the blood brain barrier (Bosch et al., 2007; Davis et al., 2000; Farris et 
al., 1998; Fernstrom and Wurtman, 1972b; Grimmett and Sillence, 2005). Free tryptophan 
competes with other large neutral amino acids (LNAA)—including tyrosine, phenylalanine, 
leucine, isoleucine, and valine—for the same transporter to cross the blood-brain barrier 
(Fernstrom, 2013). This facilitated transporter is called the L-system. It has little dependence upon 
pH and no sodium dependence. LNAA, including tryptophan, are transported down their 
concentration gradients via the L-system (Rapoport, 1976). The concentrations of the amino acids 
found in plasma are normally much lower than the Km values and saturation capacity of the 
transport system (Rapoport, 1976). The facilitated diffusion of tryptophan into the brain is a linear 
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function of concentration up to many times plasma levels (Rapoport, 1976). Once inside the brain, 
tryptophan can be used to synthesize serotonin, a biogenic amine with many functions, some of 
which will be discussed in the following sections. 
“An excessive plasma concentration of one of a competing set of amino acids reduces brain 
uptake of others of the set, thereby modifying synthesis of protein, myelin, and neurotransmitters, 
and altering cellular respiration and replication” (Rapoport, 1976). A lot of what is known about 
competition between amino acids for entry into the brain is known because of aminoacidurias, 
diseases in which an individual lacks critical enzymes necessary in amino acid metabolism. 
Phenylketonuria, for example, occurs in people with a deficiency of phenylalanine hydroxylase, 
an enzyme necessary to convert phenylalanine to tyrosine. As a result, phenylalanine and its 
metabolic byproducts build up in the blood and have neurotoxic effects. All babies born in the 
United States are now tested for phenylketonuria at birth; if treated with a diet low in phenylalanine 
and high in the essential amino acids that compete with phenylalanine, detrimental effects such as 
mental retardation can be prevented. Understanding the etiology of this disease provided 
researchers with an understanding of the competitive inhibition between amino acids with similar 
structural and chemical properties for transport across the blood-brain barrier. High blood 
phenylalanine impairs serotonin synthesis by interfering with tryptophan transport into the brain. 
Serum serotonin is decreased in phenylketonuric patients and brain serotonin is decreased in 
phenylalanine-loaded animals. (Rapoport, 1976) 
SEROTONIN 
Location 
 Serotonin is an indoleamine found throughout the body and functions in several different 
systems. Most (80-95%) of serotonin in the body is located within the gastrointestinal tract, 
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specifically in enterochromaffin cells and in enteric neurons (Kim and Camilleri, 2000). Here, 
serotonin plays a crucial role in gut secretion, motility, and sensation (Yao et al., 2011). Serotonin 
is also an important constituent of platelets and contributes to blood coagulation (Kim and 
Camilleri, 2000). Although serotonin is a hormonally active substance in the blood, it does not 
have a direct effect on the brain because of the blood-brain barrier (Voet and Voet, 1995). Instead, 
precursors are transported across the barrier and serotonin is synthesized in the central nervous 
system, where it influences cognition, sleep, mood, and appetite. Serotonin is also a factor in some 
neurological conditions including depression, anxiety disorders, schizophrenia, and eating 
disorders (Yao et al., 2011). Scientists credit the multiple roles of serotonin as a hormone and a 
neurotransmitter to evolutionary opportunism rather than to related physiological significance 
(Voet and Voet, 1995). 
 The cell bodies of serotonergic neurons are located in the dorsal raphe nucleus of the 
midbrain. However, these neurons have projections extending to many regions of the brain and 
have different influences on mood and cognition, shown in Figure 1.7. 
There are at least thirteen different G protein-coupled receptors that mediate serotonin 
activity as a neurotransmitter (Hannon and Hoyer, 2008). Some receptors are specific to certain 
areas of the brain and on the serotonergic neurons themselves. Based on structure, transduction 
properties, and mode of operation, these receptors are divided into seven types (5-HT1 through 5-
HT7) (Hannon and Hoyer, 2008). Corr (2006) describes these receptors in more detail: the two 
main presynaptic receptors are 5-HT1A, which slows neuronal firing, and 5-HT1D, which detects 5-
HT in the synapse. When 5-HT1D is occupied, release of 5-HT is inhibited. Postsynaptic receptors 
include 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT3, and 4-HT4 (Corr, 2006). Serotonergic neurons 
also contain norepinephrine receptors that modulate 5-HT release (Corr, 2006). In addition, 
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serotonergic neurons in the dorsal raphe nucleus can be inhibited by GABAergic interneurons from 
the prefrontal cortex (Robbins, 2005). These examples demonstrate the interconnectedness of 
neural pathways. Although a lot of research in psychology and pharmacology is devoted to further 
understanding the complex functions and mechanisms of modification of serotonin receptors, drug 
effects are oftentimes non-specific and influence more than one transmitter system (Mench and 
Shea-Moore, 1995). Hannon and Hoyer provide a more detailed review of 5-HT receptors (2008). 
Metabolism 
Once tryptophan crosses the blood-brain barrier, brain serotonin biosynthesis occurs in a 
two-step process, shown in Figure 1.8. First, tryptophan is hydroxylated into 5-hydroxytryptophan 
(5-HTP) by tryptophan hydroxylase. This is the rate-limiting step. Oxygen and tetrahydrobiopterin 
also form dihydrobiopterin in this first step. Next, 5-HTP decarboxylase, a PLP-dependent 
enzyme, cleaves the carboxyl group from 5-HTP to produce 5-hydroxytryptamine (5-HT), also 
known as serotonin (Voet and Voet, 1995). Serotonin biosynthesis rates are about 20 times higher 
in neuron cell bodies than in terminals (Boadle-Biber, 1993). 
 In the central nervous system, serotonin is inactivated primarily by reuptake by 
serotonergic neurons. Highly selective sodium- and chloride-dependent membrane transporters 
recycle the neurotransmitter back to terminal buttons (Corr, 2006). A lot of research has been 
dedicated to understanding the serotonin transporter gene (5-HTT), which is involved in serotonin 
transmission, early brain development, adult neurogenesis, and plasticity (Corr, 2006). Serotonin 
can also be destroyed by monoamine oxidase and aldehyde dehydrogenase, yielding 5-
hydroxyindole acetic acid (5-HIAA) (Kim and Camilleri, 2000). Melatonin is another potential 
metabolite of serotonin. Melatonin is a hormone primarily produced in the pineal gland but some 
biosynthesis also occurs in the retina and gastrointestinal tract (Esteban et al., 2004). Melatonin 
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synthesis increases in the evening and is critical in the maintenance of the circadian clock (Piccione 
et al., 2005).  
Because the hydroxylation of tryptophan is the rate-limiting step in serotonin biosynthesis, 
an increase in brain tryptophan can potentially double serotonin synthesis (Bosch et al., 2007). 
Esteban and others (2004) showed that, under normal conditions, the rate-limiting enzyme 
tryptophan hydroxylase is far from being saturated by its substrate. The availability of cofactors 
such as magnesium, vitamin B3, and vitamin B6 may also play a role in the hydroxylation of 
tryptophan (Alberghina et al., 2010b).  
Two-thirds of the tryptophan available for serotonin biosynthesis comes from intracellular 
degradation. Diet serves as the secondary source but only 1-2% of dietary tryptophan is converted 
to serotonin (Yao et al., 2011). While these proportions may seem low, the rate of serotonin 
synthesis has displayed more sensitivity to its dietary precursor than any other any other 
neurotransmitter (Fernstrom, 2013). Further evidence suggests that the amount of tryptophan 
available to the brain may influence serotonin biosynthesis. Studies have shown an increase in the 
main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), as a result of large doses of 
tryptophan (Fernstrom and Wurtman, 1974). Increasing dietary tryptophan stimulates an increase 
in brain serotonin synthesis in several species (Adeola and Ball, 1992; Laycock and Ball, 1990; 
Leathwood, 1987; Shea et al., 1990). Conversely, tryptophan depletion can be achieved by 
providing a tryptophan-free diet. Because tryptophan depletion creates a significant reduction in 
brain serotonin synthesis and release, it is a valuable tool used to study the brain serotonergic 
system and pharmacology effecting that system (Bell et al., 2001; Kantak et al., 1980).  
In human medicine, drugs that increase serotonergic activity are used to treat a range of 
psychological and neurological conditions. These compounds act on various serotonin receptors 
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to stimulate more neurotransmitter release and/or to inhibit reuptake of the neurotransmitter from 
the synaptic cleft. Other drugs inhibit monoamine oxidase activity, reducing the rate of serotonin 
degeneration. Additional treatments directly or indirectly effect dopamine, norepinephrine, and 
GABA pathways. 
The serotonin syndrome is a consequence of excess serotonergic agonism in the central 
nervous system and has been seen across species, including humans, monkeys, rabbits, mice, and 
rats (Boyer and Shannon, 2005; Gillman, 1999). Serotonin syndrome has been associated with the 
use of MAOIs, tricyclic antidepressants, SSRIs, opiate analgesics, anti-migraine drugs, herbal 
products, and other drugs (Boyer and Shannon, 2005). The severity of the condition ranges from 
barely perceptible to lethal and presents a spectrum of clinical findings in people. Symptoms 
include: tremor, hyperreflexia, spontaneous muscle spasms, muscle rigidity, hyperthermia, 
agitation, sweating, shivering, diarrhea, incoordination, and delirium (Boyer and Shannon, 2005). 
The combination of serotonergic drugs has induced the rapid onset (minutes to hours) and 
progression of serotonin syndrome (Gillman, 1999). A single dose of an SSRI has also been 
observed to cause serotonin syndrome (Boyer and Shannon, 2005). 
In the past, serotonin syndrome has been misdiagnosed as neuroleptic malignant syndrome, 
which presents with many of the same symptoms as serotonin syndrome but is caused by dopamine 
antagonists instead of serotonergic drugs (Sternbach, 1991). There are only a few distinguishing 
symptoms between the two conditions; namely that patients presenting with serotonin syndrome 
typically have hyperactive gut sounds and dilated pupils (Boyer and Shannon, 2005). Nonetheless, 
patient medication history is extremely important in accurate diagnosis and treatment of serotonin 
syndrome. In mild to moderate cases, supportive care and cessation of proserotonergic agents is 
effective at alleviating symptoms associated with the syndrome (Boyer and Shannon, 2005). 
!
 9 
Sedation, paralysis, intubation, and treatment with 5-HT2 blockers may be necessary in life-
threatening cases (Boyer and Shannon, 2005; Gillman, 1999). Many cases of serotonin syndrome 
can be resolved within 24 hours; however, symptoms may persist in patients taking longer acting 
drugs (Boyer and Shannon, 2005). 
FACTORS IMPACTING RATE OF SEROTONIN SYNTHESIS 
The rate of brain serotonin synthesis depends on a number of things, including age, sex, breed, 
social status, level of arousal, and other individual characteristics. External factors such as diet and 
exercise can also impact the rate of serotonin synthesis. 
Age 
Some researches have reported that the permeability of the blood-brain barrier decreases 
with age (Grimmett and Sillence, 2005). In accordance with this line of thought, higher plasma 
tryptophan and serotonin levels are seen in foals than in adult horses (Ferlazzo et al., 2012). 
However, one study showed a positive correlation between age and plasma tryptophan throughout 
the first year in a foal’s life (Alberghina et al., 2014). These data suggest that throughout a horse’s 
lifetime, the permeability of the blood-brain barrier stops increasing, stabilizes, and eventually 
decreases. Farabollini et al. (1988) found that neonatal rats given serotonin antagonists were less 
anxious and responded more to environmental and social cues as adults. However, brain serotonin 
levels and turnover are similar in control and animals treated neonatally, suggesting that early 
effects may change receptor sensitivity (Farabollini et al., 1988). 
Breed 
While there is some evidence supporting the effect of breed and genetics on tryptophan 
availability/serotonin biosynthesis, their mechanisms remain unclear. One study noted that 
Arabian-type horses have higher plasma tryptophan than Anglo-Arabians (Alberghina et al., 
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2014). In another study, Bagshaw et al. (1994) found that resting serum serotonin is lower in 
Arabian mares than in Standardbred mares. However, serum tryptophan concentrations were not 
significantly different between the two breeds. A separate group of researchers saw lower blood 
serotonin in Arabian mares compared to Swedish Warmblood mares, even though all horses were 
fed the same diets and housed in the same conditions (as cited in Grimmett and Sillence, 2005). It 
is unclear whether breed differences relate to differing absorption, transport, metabolism, and/or 
excretion of tryptophan. Momozawa and others (2006) investigated polymorphisms in the equine 
serotonin transporter gene, which controls serotonin reuptake from the synaptic gap. However, of 
the haplotypes identified, none were associated with anxiety scores determined through caretaker 
questionnaire.  
Sex 
Research evaluating gender differences in serotonin biosynthesis in the human brain report 
conflicting results (as cited in Kim and Camilleri, 2000). However, research in animals tends to 
suggest that females are more sensitive to dietary changes in tryptophan than males. Dickson and 
Curzon (1986) reported that female rats that were fed tryptophan were more likely to exhibit side 
effects liked to serotonin syndrome than their male counterparts. Rouvinen et al. (1999) 
supplemented silver foxes with tryptophan over the course of several months. While females 
showed reduced fear and increased exploratory behavior, the same response was not seen in males. 
Henry and others found that female swine have less hypothalamic serotonin and are more sensitive 
to dietary changes in amino acid ratio than males (Henry et al., 1992; Henry et al., 1996). Not only 
do female and male (neutered and intact) pigs have different concentrations of serotonin and 5-HT 
metabolites in the brain, but the areas that seem to have the most serotonergic activity vary (Henry 
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et al., 1996). These studies provide evidence that androgens inhibit serotonergic function in male 
rats and boars. 
Other researchers have noted that female rats are more vulnerable than males in models of 
depression and show less sensitivity to serotonin receptor agonists (Kennett et al., 1986). In 
addition, female rats seem less sensitive than males to neonatal manipulation with serotonin 
receptor agonists or antagonists; possibly because of interaction between the developing serotonin 
system and testosterone (Albonetti et al., 1994). 
Social status 
Some studies show that subordinate animals have higher levels of serotonin, yet may be 
less sensitive to tryptophan supplementation than their dominant counterparts (Mench and Shea-
Moore, 1995; Raleigh, 1987). A different study showed that dominant males have twice as much 
blood serotonin than submissive males (Mench and Shea-Moore, 1995). These researchers 
hypothesized that the dominant animals were metabolizing more dietary tryptophan to serotonin 
peripherally instead of in the central nervous system. 
Level of arousal 
Several researchers have provided evidence that serotonin synthesis and precursor 
sensitivity are greater at higher states of arousal. This is probably because more neurotransmitter 
is released when the neurons fire more frequently (Young, 1991). A study by Trulson (1979) 
provides support for this hypothesis, showing dorsal raphe activity in cats increases with state of 
arousal. In addition, Chamberlain et al. (1987) concluded that altered tryptophan levels in the diet 
influence aggression in vervet monkeys more reliably at higher levels of arousal. Firing of action 
potentials may enhance tryptophan uptake into 5-HT neurons via a carrier specific to these neurons 
and/or tryptophan hydroxylase activity may be enhanced as a result of neuronal firing. In an in 
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vitro experiment, an increase in serotonin synthesis was only observed in the presence of electrical 
field stimulation, even though available tryptophan was the same in stimulated and unstimulated 
tissues. However, in vivo studies consistently show that administration of exogenous tryptophan 
enhances 5-HT formation; this may be reflective of the fact that 5-HT neurons fire tonically in vivo 
(as cited in Boadle-Biber, 1993). Additionally, Schaechter and Wurtman (1990) provide evidence 
that elevating tryptophan levels in the rat hypothalamus proportionally increases 5-HT levels and 
release; these data support the hypothesis that serotonin release is proportionate to intracellular 
serotonin levels. 
Other Individual Characteristics 
There is some evidence in the literature that tryptophan supplementation is most effective 
in individuals who exhibit dysregulation of behaviors that may be under control of the serotonergic 
system. For example, Bell and others (2001) performed a study in humans which showed that 
healthy individuals experienced some mood lowering, memory impairment, and an increase in 
aggression due to tryptophan depletion. However, patients who had been treated for depression or 
panic disorder and responded well to antidepressants (particularly serotonergic agents), 
experienced a relapse. Interestingly, patients with untreated depression experienced no worsening 
in mood symptoms. These findings suggest that individual serotonergic systems may vary in 
sensitivity even when factors such as age and sex are held constant. Further support is provided 
Weld and others (1998), who saw changes in serotonin turnover (evidenced by concentrations of 
5-HIAA in cerebral spinal fluid) as a result of tryptophan supplementation only in animals who 




We have already discussed how the amount of tryptophan in the diet has an impact on 
serotonin biosynthesis. As shown in Figure 1.9, the profile of other nutrients in the diet can 
influence the amount free tryptophan available for transport transport into the central nervous 
system and for serotonin synthesis.  
The release of insulin triggers the uptake of free amino acids into peripheral tissues such 
as muscle (not the brain). However, because most tryptophan is bound to albumin, the rate of 
absorption into peripheral tissues is slower. As a result, the ratio Trp:LNAA increases, favoring 
tryptophan uptake by the brain and, furthermore, serotonin synthesis (Bellisle et al., 1998). 
Fernstrom and Wurtman (1972b) conducted a study in which insulin was administered to fasted 
rats. Surprisingly, this increased total plasma tryptophan up to 40% while also decreasing the 
concentration of other LNAA in the plasma. Two hours after receiving the insulin, brain 
tryptophan levels were elevated by 36% and brain serotonin levels were elevated by 28%. Research 
by Noble and others (2007) provides further supporting evidence in the role of insulin in serotonin 
biosynthesis by showing that plasma tryptophan follows the glycemic response after meal-feeding 
Thoroughbred horses. Additionally, the Trp:LNAA ratio peaked after horses were fed a “starch 
and sugar” meal but stayed relatively constant in horses fed a “fat and fiber” meal (Wilson et al., 
2007). There is some discrepancy in the literature, however; Alberghina and others (2010b) found 
that horses kept on a high fiber diet had higher plasma serotonin and tryptophan levels than horses 
fed a high starch diet. The conflicting results of this study may be because blood samples were 
taken three and six hours after feeding—at least an hour after the spikes in insulin, serotonin, and 
tryptophan were reported in previous studies. Also, Kim and Camilleri (2000) claim that plasma 
measurements of serotonin are often inaccurate, since serotonin is easily released with the agitation 
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and lysis of platelets. Wurtman (2011) draws the association that “carbohydrate cravers” may be 
unknowingly attempting to increase serotonin synthesis using this mechanism in order to 
compensate for disorders linked with low serotonin.  
 High fat diets (or lipolysis) may also increase the amount of free tryptophan available to 
the central nervous system, as non-esterified fatty acids displace tryptophan from its binding site 
on albumin (Bosch et al., 2007). High protein diets increase plasma tryptophan levels but, because 
of the corresponding increase in competing LNAA, brain tryptophan and serotonin do not increase. 
Removing the competing amino acids from the diet has been shown to increase tryptophan and 
serotonin (Fernstrom and Wurtman, 1972a). 
Exercise 
There is evidence that exercise increases free tryptophan, the tryptophan to LNAA ratio, 
and brain serotonin (as cited in Bruschetta et al., 2013; Farris et al., 1998). Exercise may increase 
free Trp:LNAA by releasing free fatty acids, which displace tryptophan from its binding site on 
albumin (Grimmett and Sillence, 2005). Additionally, multiple studies have looked at the effects 
of tryptophan and/or serotonin in central fatigue during exercise but the results are conflicting and 
range from a negative correlation between serotonin and exercise endurance to the absence of an 
effect between tryptophan supplementation and time until exercise fatigue (Alberghina et al., 
2010a; Bruschetta et al., 2013; Farris et al., 1998; Piccione et al., 2005; Vervuert et al., 2005). 
Some researchers believe that exercise releases peripheral serotonin from platelets, which is 
transported in the plasma to neurons or vascular endothelial cells (Alberghina et al., 2010a; 
Bruschetta et al., 2013). Whether it be through serotonin release from platelets, decreased 
motivation, or increased survival methods, the mechanisms by which serotonin impacts exercise 
endurance have yet to be elucidated. 
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TRYPTOPHAN SUPPLEMENTATION IN HORSES 
Research in cattle, poultry, swine, dogs, foxes, humans, mice, fish, and monkeys have 
shown sedative effects, including decreases in aggression, fear, stress, depression, stereotypic 
behavior, and/or overall activity level, as a result of various doses of tryptophan (as cited in 
Grimmett and Sillence, 2005). For a review of these studies, see Table 1.1. However, other than 
slight effects seen in one study, no research has been able to show a behavioral effect in horses. 
This suggests that there may be a potential difference in tryptophan doses required to achieve 
specific behavioral effects in horses. 
 Bagshaw et al. (1994) conducted the first study assessing the behavioral effects of 
tryptophan supplementation in horses. However, the doses given to horses were less than 1% of 
the average amount of tryptophan administered using the commercial supplements available today. 
These researchers actually found that tryptophan supplementation corresponded with a significant 
increase in activity both when horses were isolated and when they had visual contact with other 
horses. However, treatment horses did show some significant decreases in heart rate throughout 
the behavioral tests and stereotypic behavior in one horse was reduced.  
 Grimmett and Sillence published a review in 2005 summarizing the current research and 
evaluating areas of future research in the use of tryptophan as a calmative in horses. Since this 
time, there has been very little research in supplementing tryptophan to equines. Malmkvist and 
Christensen (2007) supplemented young horses with a commercial tryptophan product but found 
no significant differences between treatment and control groups with respect to mean heart rate or 
behavioral observations taken during a voluntary approach test and handling test. Another study 
by Noble et al. (2008) looked at the effects of supplementing horses with a commercial dose of L-
tryptophan on plasma tryptophan levels and response to approaching a novel object/person. Results 
!
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showed that plasma tryptophan levels increased three-fold as a result of supplementation. The ratio 
of tryptophan to other large neutral amino acids also increased. However, no significant behavioral 
effects were noted. 
 Paradis et al. (1991) evaluated toxicity effects of tryptophan supplementation in horses, 
either via oral administration or intravenous infusion. They found that plasma tryptophan 
concentrations peak after dosing and return to pre-dosing levels within 48 hours. These researchers 
also demonstrated that orally administered tryptophan can be metabolized into 3-methylindole or, 
more commonly, indole. Both of these compounds may have toxic effects, causing hemolytic 
anemia and/or respiratory distress. These consequences were seen in one of the four ponies 
receiving 350 mg tryptophan/kg bodyweight and in three of the four ponies receiving 600 mg 
tryptophan/kg bodyweight.  
 It is clear from the evidence, or lack thereof, provided by previous research that the safety 
and efficacy of using tryptophan as a calmative in horses warrants further investigation. However, 
supplement companies continue to market products containing tryptophan to horse owners, 
insuring that the ingredient is safe and effective for use in equines. For a review of these products, 
see Table 1.2. Horse owners find these supplements appealing because they do not require 
veterinary oversight yet promise a safer, more relaxed, and easy-to-ride horse. 
!
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TABLE 1.1: Review of research supplementing tryptophan to various species 




Young et al., 1986 Human males ~129 mg/kg 1x increase self-reported depression symptoms 
Liebermann et al., 
1986 
Humans 50 mg/kg 1x sedative effect 
Nakanishi et al., 
1997 
Calves 160 mg/kg 7d 
calves supplemented with tryptophan showed increased 
lying time and decreased exploratory behavior in the 
two-weeks post weaning; feed utilization was not 
different between treatment and control calves. 
Laycock & Ball, 
1990 
Chickens 5000 mg/kg 6d 
hysteria episodes decreased; feed consumption increased, 
egg laying increased; plasma Trp increased 





4 - 20 weeks of 
age 
Birds fed supplemental tryptophan showed less 
aggressive pecking; low levels (0.38%) were as effective 
as high levels (1.5%) 
DeNapoli et al.,  
2000 
Dogs 
Low protein, low 
Trp; low protein, 
high Trp; high 
protein, low Trp; 
high protein, high 
Trp 
daily, 7d 
No differences in fearfulness between diets; dogs on high 
protein diet supplemented with Trp showed less 
dominance aggression than dogs feed a high protein diet 
without Trp; dogs on low protein diet with supplemented 
Trp showed less territorial aggression than dogs fed a 
low protein diet without supplemental Trp 
Paradis et al., 1991 Horses 350 mg/kg 
1x, feed 
withheld for 
24hrs prior to 
admin 
Four ponies developed hemoglobinuric nephrosis and 
bronchiolar degeneration; one pony also developed 
hemolysis, hemoglobinuria, and increased respiratory 
rate 
Paradis et al., 1991 Horses 100 mg/kg IV 
1x, feed 
withheld for 
24hrs prior to 
admin 





Paradis et al., 1991 Horses 600 mg/kg 
1x, feed 
withheld for 
24hrs prior to 
admin 
Four out of five ponies showed restlessness, increased 
respiratory rate, hemolysis, and hemoglobinuria 
Bagshaw et al.,  
1994 
Horses 0, 0.05, & 0.1 mg/kg 
1x, 2h prior to 
testing 
Horses dosed with 0.1 mg/kg had higher rates of 
walking/sniffing and heart rate during isolation 
compared to horses dosed with 0 mg/kg; one horse 
showed a reduction in sterotypic head twisting after 
being dosed 
Noble et al., 2008 Horses 12.5 mg/kg 1x 
plasma Trp increased, with peak 1.5-2 hours post-dosing; 




Horses 12.9 mg/kg 
1x, 2-3h prior to 
test 
No difference in heart rate or novel stimulus approach 
test  
Farris et al., 1998 Horses 
100 mg/kg IV: 
glucose with Trp; no 
glucose with Trp; 
glucose without Trp; 
no glucose, no Trp 
1x 
Horses dosed with tryptophan immediately before 
exercise and either glucose or a placebo during exercise 
had a lower mean time to exhaustion than horses dosed 
with two rounds of placebos; these horses also had 
higher plasma prolactin. 
O'Reilly, 2006 
(Thesis) 
Horses 3g 5x/day 21d Tryptophan had no effect on cribbing behavior 
Adeola & Ball,  
1992 
Pigs 
0, 5, 10, 25 g Trp/kg 
diet 
5d 
doubled plasma Trp; pigs showing higher stress pre-
slaughter had lower hypothalamic serotonin content; ; 
reduced PSE score; hypothalamic serotonin 
concentration increased with Trp supplementation but 
the increase peaks at day 5 and then decreases: 
researchers suspect an adaptive response 
Shen, et al., 2015 Pigs 0.0% & 0.8% 12d 
Piglets fed diets with 0.8% Trp had a higher average 
daily gain and feed efficiency and lower salivary cortisol 




Shen et al., 2015 Pigs 
0.0%, 0.8%, & 0.7% 
(with the same 
amino acid ratios as 
0.8%) 
16d 
Pigs fed diets supplemented with Trp had better feed 
efficiency 
Koopmans et al., 
2005 
Pigs 
diets with high and 
normal Trp:LNAA 
7d and 12d 
Pigs at the higher level of supplementation showed 
higher plasma Trp, lower basal plasma cortisol, lower 
basal plasma noradrenaline, but no difference in plasma 
adrenaline concentrations compared to controls; during 
social stress, pigs on the higher tryptophan diet showed 
less avoidance behavior, but similar amounts of physical 
activity and aggression; post-stress plasma cortisol, 
noradrenaline, and adrenaline were less in pigs provided 
supplement. 
Peeters et al., 2004 Pigs 
5 g/L in drinking 
water 
3d 
Pigs that received tryptophan spent significantly more 
time lying down during simulated transport 




7d, 3d, 3d 
Trp-supplemented pigs spent more time laying, less time 
eating, and less time fighting 
Poletto et al., 2014 
Pigs (gestating 
sows) 
~66 mg/kg 7d 
Trp-supplemented sows showed less aggression and 
increased exploratory behavior when mixed with other 
sows 
Martinez-Trejo  




3d before and 
after weaning 
(6d total) 
Highest levels of tryptophan supplementation show less 




50, 75, 100, 125, 200 
mg/kg 
intraperitoneal 
1x, 60 min prior 
to test 
Antidepressant-like effects in Porsolt's Swim Test 
At 125 and 200 mg/kg injection, response was no 
different than control 
Janczak et al., 2001 Mice 
2.08 g/L in drinking 
water 
dialy for 2 
weeks before 
behavior test 
Mice treated with tryptophan showed reduced 
exploratory behavior in resident-intruder test, number of 








2 µM Tryptophan 
superfused over 
130 min 
Superfusing hypothamalic slices with medium containing 
tryptophan increases total serotonin release by 115.0 ± 
5.9%. Superfusing tryptophan in the medium also 
increases electrically-stimulated total serotonin release 
by 125.9 ± 3.9%. In slices with reduced tryptophan 
levels (due to leucine supplemented medium), total 
serotonin release decreased by 88.7 ± 2.0%. 
Esteban et al., 2004 Rats 300 mg 5d 
Rats that received tryptophan during the day (8:00), there 
was an increase in 5-HT and 5-HIAA in the brain; rats 
that received tryptophan at night (20:00), the 5-HT/5-
HIAA did not change but there was a significant increase 
in circulating melatonin 
Basic et al., 2013 Salmon 
Control diet, 2x Trp, 
3x Trp, 4x Trp 
7d 
Trp supplemented fish had lower basal levels of cortisol 
1 and 10 days after supplementation stopped 
Rouvinen et al.,  
1999 
Silver Foxes 1.2 g/MJ ME 4 months 
Supplementing Trp increased exploratory behavior in 
females; Trp did not have a significant effect on fur 




10, 20, 40 mg/kg 6d 
Monkeys showed dose-dependent increases in eating, 
and decreases in locomotion, vigilance, and aggression 







1x; observed 5 
hours after 
Male and females on Trp-supplemented diet showed 
reduced competitive aggression; when males were given 
a mixture containing no Trp, spontaneous and 
competitive aggression increased 




100 mg/kg, twice per 
day 
21d 
In monkeys with a history of self-injurious behavior, the 
supplement reduced the behavior and increased serotonin 
turnover (measured by concentrations of 5-HIAA in 
CSF). Serotonin metabolism and behavior were not 





TABLE 1.2: Summary of paste supplements containing tryptophan available to horse owners in the United States 
 





Divine Equine  
(Oralx Corp., Ogden, UT) 
administer 4 hours before 
stressful event 3.4 
valerian root, black cohash, passion flower, ginger root, hops, wood betony, cherry extract for flavoring, benzol alcohol 
.05%, sorbic acid as a preservative, xanthan gum 
SmartCalm Ultra Paste  
(SmartPak Equine, 
Plymouth, MA) 
administer 2-4 hours before 
stressful event 2 
active: magnesium, taurine, inositol, thiamine, vitamin e 
inactive: ascorbyl palmitate, artificial flavor, citric acid, coconut oil, methylparaben, silicon dioxide, soy lecithin, vegetable 
oil (cold pressed), vitamin e supplement 
B-Kalm  
(Farnam Companies, Inc., 
Phoenix, AZ) 
administer 1.5-2 hours prior 
to exercise 20 
inactive ingredients: dextrose, ethyl alcohol, ground limestone, potassium sorbate, sodium bentonite, sodium benzoate, 
sodium saccharin, thiamine hydrochloride with artificial flavor and color, water, and xanthan gum 
Vision  
(VitaFlex Nutrition, Council 
Bluffs, IA) 
administer 2 hours before 
competition/race/trailering 5 
active: thiamine, inositol, riboflavin, magnesium, vitamin b6, valerian root extract 
inactive: artificial flavoring, corn starch, glucose, glycerin, maltodextrins, methylparaben, propylparaben, silicon dioxide, 
sorbic acid, sorbitol, sucrose, water 
Tryptoplex  
(Oralx Corp., Ogden, UT) 
administer 2 hours prior to 
event 3.4 
water, magnesium amino acid hydrochloride, pyridoxine hydrochloride, ginger glycyrrhiza, juniper berries, cherry extract 
for flavoring, benzoic acid (a preservative) sorbic acid ( a preservative) xanthan gum 
Calmex-V  
(Med-Vet Pharmaceuticals, 
Eden Prarie, MN) 
2-4 hours prior to 
trailering/riding when 
needed; may be given 24 and 
48 hours prior to 
trailering/riding 
1.5 active: valerian root, thiamine, taurine, inositol 
inactive: distilled water, glycerin, sodium propionate, xanthan gum 
Easy Going  
(ProFormula Laboratories, 
Inc., Ft. Lauderdale, FL) 
administer 3 hours prior to 
event 8.08 
valerian root, passion flower, kava kava, ginger root, hops, wood betony, ethyl alcohol, aloe vera gel, .05% potassium 
sorbate as a persvative, acacia gum 
Quietex II  
(Farnam Companies, Inc., 
Phoenix, AZ) 
administer 2 hours before 
training or competition 5 
active: thiamine, inositol, magnesium, vitamin b6, valerian root extract 
inactive: corn starch, glucose, glycerin, malt syrup, maltodextrins, methylparaben, propylparaben, silicon dioxide, sorbic 
acid, sorbitol, sucrose, water 
EQUI+Calm 
(Equine Healthcare 
International, Aberdeen, NC) 
administer once the night 
before and once the morning 
of performance; additional 
tubes can be administered at 
6-12 hour intervals 
not 
quantified 
active: magnesium, melatonin, arginine, leucine, theanine, thiamine, phenylalanine, bismuth 
inactive: maple flavor, praline flavor, deionized water, vitamin c, glycerine, xanthan gum, methyl paraben, propyl paraben, 
acesulfame k sweetner 
Perfect Prep EQ Extreme 
Paste  
(Perfect Products, LLC, 
Morrow, OH) 
feed 90 minutes before 
increased stress; effects 




active: magnesium, inositol, thiamine 
proprietary blend: soybean oil, magnesium amino acid chelate, thiamine mononitrate, soy lecithin, inositol, silica gel, 





Perfect Prep EQ Supreme 
Paste  
(Perfect Products, LLC, 
Morrow, OH) 
administer 90 minutes prior 
to activity; adjust for desired 
results; effects begin 1 hour 
after administration and can 
last up to 6 hours 
not 
quantified 
active: magnesium, inositol, thiamine, l tryptophan, vitamin “behave” (a proprietary blend of b vitamins) 
proprietary blend: soybean oil, magnesium amino acid chelate, thiamine mononitrate, soy lecithin, inositol, silica gel, 
vitamin e supplement, citric acid, natural & artificial flavors, pyrodoxine hcl, riboflavin, ascorbyl palmitate, methylparaben, 
coconut oil 
Oxy-Calm  
(Meal and More, Inc., 
Morrice, MI) 
feed 2 hours before event; 




vitamin e supplement, sugars, salt, flavorings, vegetable oil, tryptophan, thiamine mononitrate, guar gum, xanthan gum, 
wheat germ oil, dried active yeast, lactobacillus acidophilus fermentation product 
At-Ease Megadose  
(Richdel, Inc., Carson City, 
NV) 
administer one dose 1-3 
hours before and one dose 
immediately before desired 
event 
2 soy oil, magnesium oxide, corn starch, thiamine mononitrate, salt, dextrose, pyridoxine hydrochloride, methyl & propyl 
paraben (a preservative), silicon dioxide, artificial apple flavoring 
Calming Oral Gel  
(Kaeco Group Inc., 
Savannah, MO) 
administer 2-4 hours prior to 
competition, event, 
transporting, etc. 
3.4 valerian root, black cohosh, passion flower, ginger root, hops, wood betony, apple flavor, benzyl alcohol .05%, sorbic acid 
as a preservative, xanthan gum 
Formula Calm B  
(dac, Dover, Ohio) 
give one to three times daily 
before and during events 0.5 
magnesium sulfate, taurine, thiamine mononitrate, inositol, gylcerin, silica gel, soybean oil, coconut oil, natural & artificial 
flavors 
Tryptophan Plus Gel  
(Horses Prefer, Menomonie, 
WI) 
feed 1.5 to 2 hours prior to 
competition, strenuous 
exercise, racing, or shipping 
not 
quantified 
dextrose, cane molasses, propylene glycol, silicon dioxide, polysorbate 80, niacinamide, pork peptone, calcium chloride, 
magnesium oxide, potassium chloride, thiamine hydrochloride, pyridoxine hydrochloride, riboflavin, lactic acid, apple 













Fig. 1.1: The biosynthesis of chorismate. Pathway enzymes: (1) 2-keto-3-deoxy-D-
arabinoheptulosonate-7phosphate synthase, (2) dehydroquinate synthase, (3) 5-
dehydroquinate dehydratase, (4) shikimate dehydrogenase, (5) shikimate kinase, 
(6) 3-enoylpyruvylshikimate-5-phosphate synthase, (7) chorismate synthase. 
Reprinted from “Biochemistry” (p. 774), by D. Voet and J.G. Voet, 1995, New 
York: John Wiley & Sons, Inc. Copyright 1995 by John Wiley & Sons, Inc.. 














Fig. 1.2: Pathways for the synthesis of tryptophan. Pathway enzymes: (1) 
anthranilate synthase, (2) anthranilate-phosphoribosyl transferase, (3) N-(5’-
phosphoribosyl)-antranilate isomerase, (4) indole-3-glycerol phosphate 
synthase, (5) tryptophan synthase, α subunit, (6) tryptophan synthase, β subunit. 
Reprinted from “Biochemistry” (p. 775), by D. Voet and J.G. Voet, 1995, New 
York: John Wiley & Sons, Inc. Copyright 1995 by John Wiley & Sons, Inc.. 







Fig. 1.3: Pathways of tryptophan degradation. Enzymes: (1) tryptophan-
2,3-dioxygenase, (2) formamidase, (3) kynurenine-3-monooxygenase, (4) 
kynureninase, PLP dependent, (5) 3-hydroxyanthranilate-3,4,-dioxygenase, 
(6) amino caroxymuconate semialdehyde decarboxylase, (7) 
aminomuconate semialdehyde dehydrogenase, (8) hydratase, (9) 
dehydrogenase, (10) α-keto acid dehydrogenase, (11) glutaryl-CoA 
dehydrogenase, (12) decarboxylase, (13) enoyl-CoA hydratase, (14) β-
hydroxyacyl-CoA dehydrogenase, (15) HMG-CoA synthase, (16) HMG-
CoA lyase. Reprinted from “Biochemistry” (p. 744), by D. Voet and J.G. 
Voet, 1995, New York: John Wiley & Sons, Inc. Copyright 1995 by John 
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Arachnoid trabecula. Arachnoid vil ( u s .  Dura mater. 
Subarachnoid spa& Falx cerebri Cortkx cevebri 
Schematic diagram of coronal section of meninges and cerebral cortcx, 
t o  show relation of arachnoid villus t o  dural venous sinus. The potential sub- 
diiral space is necessarily shown of greater size than is normal; the subarachnoid 
space over the convolutions is also increased in width t o  illustrate the character 
of thc subarachnoid mesh. 
Fig. 1 
from the deposits of precipitated granules. This characteristic 
of the lining cells also prevented the passage of the foreign solution 
diffusely into the nervous tissue through the pia mater. Some- 
what similarly, there was no penetration of the ferrocyanide- 
citrate solution, as evidenced by the precipitation, inward dong 
the perivascular spaces. These channels, as shown diagrammati- 
caIly in figure 2, connect directly with the subarachnoid space, 
the cells of the pia mater turning inward to form the outer layer 
of the cuff and the arachnoidal elements forming the inner 
covering. Under the conditions of injection, with maintenance 
of normal pressure relations within the subarachnoid space, 
these perivasculsr cuffs were found to be free from the granules; 
occasionally in the outer funnel-shaped dilatation (fig. 2) of the 
channel precipitated granules were identified. The evidence, 
Fig. 1.4: The subara i  space. When there is no difference in pressure 
between the subarachnoid space and the venous blood, there are numerous 
microvilli made up of layers of overlapping endothelial cells on the arachnoid 
membrane. Reprinted from “The absorption of cerebrospinal fluid into the 
venous system,” by L.W. Weed, 1923, American Journal of Anatomy, 31(3), 
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foot process 
FIGURE 1. Diagram illustrating the close association of endothelial cells in brain capillaries 
with foot processes extending from astrocytes. The blood-brain barrier is produced by the 
continuous endothelium. The astrocytes encircle the microvessels, but are not sealed together 
and interstitial fluid has access (arrows) to the basement membrane and abluminal surface of 
the endothelial cell. 
The astrocyte seems a likely candidate for mediating this effect of brain tissue 
upon capillary structure and function. Ultrastructural studies of regions of the brain 
without a bamer, astrocytic brain tumors, and microvessels in the retina support this 
hypothesis. Several small regions of the brain stem and hypothalmus are involved in 
neuroendocrine feedback and are more permeable than the rest of the brain? Micro- 
vascular endothelial cells in these areas are fenestrated and lack the special features 
found elsewhere in the brain. The characteristic close apposition of astrocytic processes 
to the endothelial cell is also absent in these regions, leaving open spaces between the 
basement membrane of the capillary and the nearby astrocytes (FIG. 3). Similarly, 
the highly permeable microvessels within astrocytic brain tumors also lack close contact 
with the transformed astrocytes.’ In contrast, microvascular permeability in the retina, 
like the brain, is markedly restricted and contributes to the formation of the 
blood-retinal bamer.* Consistent with the proposed role of the astrocyte in brain 
capillary differentiation, the retinal microvessels are also surrounded by foot processes 
from astrocytes’ (FIG. 4). 
The constant close association between astrocytes and endothelial cells in areas of 
the brain and retina with a barrier, and the lack of these contacts in tumors and brain 
regions without a barrier together with the transplantation studies, provide the in vivo 
evidence for attributing formation of the BBB to an interaction between astrocytes 
and endothelial cells. The development of methods to isolate endothelial cells and 
astrocytes from brain and to grow the two cell types separately in culture provides a 
new approach for studying features of their interaction that may be important to 
formation of the BBB. 
Fig. 1.5: Brain capillary-glial cell junction. The endothelial cells in 
the brain capillaries are closely associated with astrocytes. 
Interstitial fluid has access at the locations indicated by the arrows. 
Reprinted from “Endothelial cell-astrocyte interactions: a cellular 
model of the blood-brain barrier,” by G.W. Goldstein, 1988, Annals 
of the New York Academy of Sciences, 529(1), 32. Copyright 2006 by 








Fig. 1.6: The choroid plexus. The basal lamina of the choroid plexus faces highly 
vascularized connective tissue. There are microvilli on the apical surface, which 
face into the cerebrospinal fluid; tight junctions regulate what compounds diffuse 
from the capillaries into the cerebrospinal fluid. Reprinted from “Mechanisms of 
CSF secretion by the choroid plexus” by T. Speake, C. Whitwell, H. Kajita, A. 
Majid, and P.D. Brown, 2001, Microscopy Research and Technique, 52(1), 50. 









Fig. 1.7: Projections of serotonergic neurons. These neural pathways are involved in various aspects of 
cognition and behavior: prefrontal cortex (mood), basal ganglia (movement, potentially obsessions and 
compulsions), limbic area (anxiety and panic), and hypothalamus (appetite and eating behavior) (Corr, 
2006). Reprinted from “Biological Psychology: An Introduction to Behavioral, Cognitive, and Clinical 
Neuroscience” (p. 93), by S.M. Breedlove, N.V. Watson, and M.R. Rosenzweig, 2010, Sunderland, MA: 













Fig. 1.8: Steps in serotonin biosynthesis. Reprinted from “Biochemistry” (p. 759), by D. 
Voet and J.G. Voet, 1995, New York: John Wiley & Sons, Inc. Copyright 1995 by John 







Fig. 1.9: Exercise and diet composition impact the rate of serotonin biosynthesis. Reprinted from 
“Calmatives for the excitable horse: A review of L-tryptophan,” by A. Grimmett and M.N. Sillence, 
2005, The Veterinary Journal, 170(1), 26. Copyright 2004 Elsevier Ltd.. Reproduced with permission. 
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CHAPTER II: EVALUATING THE EFFECTIVENESS OF VARYING DOSES OF 
SUPPLEMENTAL TRYPTOPHAN AS A CALMATIVE IN HORSES 
INTRODUCTION 
Tryptophan is often marketed in the horse industry as a calmative supplement, claiming to 
encourage focus and relaxation while reducing tense, nervous, and spooky behavior. Horse owners 
frequently utilize calming products in situations including transportation, competition, and other 
novel training events. Tryptophan is the amino acid precursor to serotonin, a neurotransmitter 
involved in mood, appetite, sleep, memory, and learning in many species, including humans. 
Psychiatrists utilize serotonin-enhancing drugs in people to treat conditions such as depression, 
anxiety, and obsessive-compulsive disorder. Tryptophan supplementation has been shown to 
increase serotonin production (Fernstrom, 2013). However, while supplementation has been linked 
to reduced aggression and fearfulness in species other than the horse, there is no current research 
within the scientific community to support any behavioral effects of tryptophan supplementation 
in horses (Grimmett and Sillence, 2005). The use of this supplement for calming purposes in horses 
remains unproven and somewhat controversial among horse owners and professionals. The 
objective of the following study is to evaluate behavioral and physiological responses resulting 
from differing dosages of L-tryptophan supplementation in the horse. Identification of a safe and 
effective dose of tryptophan in horses could give owners a non-prescriptive, non-invasive tool to 
manage potentially dangerous situations. In addition, feed and supplement companies may benefit 
from the results of this study, recognizing new dosages or potential additives in products marketed 
to horse owners. 
Because tryptophan competes with other amino acids to bind to transport proteins and cross 
the blood-brain barrier, scientists are now using the ratio of tryptophan to other large neutral amino 
!
 30 
acids (LNAA) to estimate serotonin production in the central nervous system (Wilson et al., 2007). 
Research has shown that serum tryptophan levels increase when horses are supplemented at a dose 
comparable to those used in commercial supplements but that there are no significant behavioral 
effects (Malmkvist and Christensen, 2007; Noble et al., 2008). Other studies have noticed a 
potential effect of diet and time of sampling on serum tryptophan levels in horses (Alberghina et 
al., 2010b; Wilson et al., 2007). While it is possible that these studies may not have seen behavioral 
effects when supplementing tryptophan because researchers were administering doses too low, 
there are also health concerns when supplementing tryptophan at doses too high. High doses of 
tryptophan may cause hemolytic anemia and symptoms of respiratory distress in horses. 
Researchers predict that these symptoms are the effect of the toxic indole metabolite produced in 
the hindgut of horses when large doses of tryptophan are administered orally (Paradis et al., 1991). 
There is a large range, from approximately 12.9 mg/kg bodyweight (Malmkvist and Christensen, 
2007) to 350 mg/kg bodyweight (Paradis et al., 1991), of oral tryptophan supplementation that has 
not been scientifically tested for behavioral or physiological effects in horses. Nevertheless, horse 
owners and trainers frequently utilize supplements containing tryptophan and/or ingredients like 
magnesium, vitamin B6, and a variety of herbs to promote a calming effect. One benefit to 
supplementing natural ingredients versus using prescription drugs is that many common dietary 
components are legal to use in show circuits whereas sedatives are banned substances (USEF, 
2015). We hypothesized that, within the untested range of tryptophan supplemented to horses, 
there is a safe and behaviorally effective dose. 
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MATERIALS AND METHODS 
Horses and Care 
The study took place December 2014-January 2015 at Colorado State University’s Equine 
Teaching and Research Center. Ten geldings and two mares were included in the experiment. 
Three of the horses were Quarter Horse type and the other nine were draft horse crosses. Horses 
ranged in age from 2.5-16 years (average 9.1 years), height from 150-169 cm (average 158.7 cm), 
weight from 462-626 kg (average 541.4 kg), and body condition score from 3-8 (average 5.2) 
(Henneke et al., 1983). Horses were divided into three groups based on bodyweight. One horse 
from Group 2 was removed from the study during the acclimation period due to handling 
difficulties. A description of the remaining horses is provided in Table 2.1. Variance between 
subjects is displayed in Table 2.2. All horses were used for trail riding and leased from a private 
owner. Informed client consent was obtained prior to the beginning of the experiment. In addition, 
all animal care and experimental procedures were approved by the Colorado State University 
Animal Care and Use Committee under protocol #14-5191A.  
All horses were dewormed with 1.87% ivermectin (MWI, Boise, ID) and evaluated by a 
veterinarian prior to being accepted into the study. Throughout the study, horses were allowed ad 
libitum access to water and salt. Expected body weight at a body condition score of 5 was 
calculated for each horse (Henneke et al., 1983). NRC (2007) requirements were calculated based 
on expected body weight. Horses were fed 0.5% of their expected body weight in concentrate, on 
a dry matter basis, per day. The concentrate provided was a commercially-available senior feed 
(Purina Animal Nutrition LLC, Shoreview, MN). Each horse’s remaining energy requirements 
were met with grass hay. Horses were housed in stalls and their daily ration divided into two 
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feedings at approximately 07:00 and 19:00 hours. Grain and hay nutrient profiles are reported in 
Table 2.2.  
In order to monitor horse health status, resting respiratory rates were monitored at feeding 
and blood collection times (three times daily) to safeguard against any signs of respiratory distress 
going unnoticed. Resting heart rate and rectal temperature were recorded during the effective dose 
time for horses receiving treatment.  
Study Design 
Horses were given a 7-day acclimation period before treatment began. There were four 
treatment levels: a negative control (CON), in which horses received no supplemental tryptophan; 
LOW, in which horses were given 20 mg Trp/kg BW; MED, in which horses were given 40 mg 
Trp/kg BW; and HIGH, in which horses were given 60 mg Trp/kg BW. Pharmaceutical grade L-
tryptophan (Ajinomoto North America, Raleigh, NC) was mixed with approximately 50 cc 
applesauce and water to create a paste-like consistency and administered orally before morning 
feeding. CON horses received an oral dose of only applesauce and water. Each treatment period 
lasted three days and there was a four-day washout period between treatments. Each horse received 
all treatments. Horses were assigned treatments in a random order so that all horses in one group 
were receiving different treatments. To ensure accurate dosing, each horse was weighed on a scale 
the morning prior to beginning a new treatment. In order to maintain consistent dose, sample 
collection, and behavior test timing, groups began the experiment on staggered start dates, spaced 
one to three days apart. Daily procedures, broken down by group, are described in Table 2.3. 
Behavior Testing 
 Horses underwent a reactivity test similar to one described by Noble et al. (2013).  The 
setup for the behavior test is shown in Figure 2.1. Footing within the chute was raked between 
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startle tests in order to try to maintain consistency despite weather conditions. Temperature, wind 
speed, and precipitation were recorded at the time of each test so that the effect of environmental 
conditions could be quantified. Each horse was individually led into the chute and held at a 
standstill for 10 seconds at a location 1 meter into the chute. Upon release, a startling sound and 
movement were made from a constant location behind the horse. A blind was set up to ensure that 
horses did not see the startling visual cue prior to stimulus presentation. The rate (m/s) at which 
the horse exited the chute (ExitSpeed) was measured using electronic timers (FarmTek, Wylie, 
TX) placed 6 meters apart on the sides of the chute. Sensors were placed 1 meter off the ground 
so that the horses’ legs or chest may break the light beam. In order to reduce habituation, the 
startling stimuli rotated between a whoosh paired with a waving flag, an alarm sound paired with 
an opening umbrella, and machine gun fire paired with a flapping plastic bag. The auditory stimuli 
were pre-recorded and consistent in volume and intensity. To minimize habituation to the startle 
test, null tests, in which there are no startling stimuli, were performed during the acclimation 
period, on day two of each treatment, and on washout days. Startle tests performed 2-3 hours after 
morning administration of tryptophan supplement on days one and three of each treatment. Each 
horse experienced either a startle or null test each day. All tests on treatment days were video 
recorded. 
Heart rate data was collected during the behavior tests using a Polar RS800CX training 
computer, which received heart rate data from a Polar WearLink W.I.N.D. transmitter attached to 
a chest strap that fitted around the horses’ heart girth (Polar Electro OY, Kempele, Finland). Hair 
around the location of the electrodes was shaved and water and/or electrode gel were used to 
improve contact with the horses’ skin. Horses remained in the stall until a consistent baseline heart 
rate was found by the heart rate monitor. After the behavior test, each horse was brought back to 
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their stall. Handlers waited for heart rate to return to baseline before removing the heart rate 
monitor. 
Heart rate data was uploaded daily via infrared communication to Polar WebLink and 
transferred to polarpersonaltrainer.com for storage. In addition to the baseline heart rate 
information, the following measurements were taken: (1) HR30: heart rate (bpm) 30 seconds post-
startle stimuli, (3) HR_Diff: HR30 minus baseline heart rate, and (4) TimetoBL: time (sec) from 
presentation of startle stimuli until baseline heart rate resumed. 
Blood Sample Collection and Analysis 
 Blood samples were collected into evacuated blood collection tubes containing either a clot 
activator or sodium fluoride (BD Vacutainer evacuated blood collection tube, Fisher Health Care, 
Chicago, IL). Blood samples were taken before morning feeding or supplementation (BC1), at 
approximately 0600, and again before horses preformed the behavior test (BC2). This was done 
on the last day of the acclimation period as well as throughout the treatment periods. Blood 
obtained from BC1 was analyzed for packed cell volume in order to monitor the health of each 
individual horse, ensuring that no horses became anemic during the study. On days one and three 
of each treatment, additional blood samples were taken both before the startle test was performed 
(BC2) and again approximately 15 minutes after the test (BC3). These samples were analyzed to 
compare glucose, lactate, and cortisol levels before and after the startle test. Blood samples were 
allowed to clot at room temperature for 45-60 minutes before being centrifuged at 2,500 rpm for 
15 minutes. Serum was then removed and stored in 0.5 mL aliquots in microcentrifuge tubes at -
20°C until further analysis. 
 BC2 and BC3 samples were analyzed for serum glucose and lactate using a YSI Model 
2700 SELECT Biochemistry Analyzer (YSI Life Sciences, Yellow Springs, Ohio). Serum glucose 
!
 35 
(mg/dL) was analyzed from sodium fluoride vacutainers. Each sample was run 2-4 times, until 
glucose concentrations read within 1% of each other. The closest two readings were then averaged 
together to obtain pre- and post-startle test serum glucose values (from BC2 and BC3, 
respectively). Post-startle serum glucose (GluPostAvg) was considered as a response variable. 
Additionally, the difference in glucose values (GluDiff) was calculated by subtracting pre-startle 
(BC2) values from post-startle (BC3) values. Serum lactate (mmol/L) was analyzed from 
vacutainers containing only a clot activator. Samples were run 2-4 times, until values within 2% 
of each other were obtained. In the same way glucose response variables were obtained, post-
startle serum lactate (LactPostAvg) and the difference between lactate pre- and post-startle values 
(LactDiff) were calculated response variables. The YSI auto-calibrated every five samples. 
Standards were analyzed before any samples, after every fifty samples, and once all samples had 
been analyzed. The date each sample was analyzed was recorded and considered as a covariate in 
the appropriate model (i.e. glucose sample run date (GluRunDate) was considered as a covariate 
for GluPostAvg and GluDiff models while lactate sample run date (LactRunDate) was considered 
as a covariate for LactPostAvg and LactDiff models). 
 Serum cortisol (mg/dL) was analyzed from BC2 and BC3 red top vacutainers using ELISA 
kits (Rocky Mountain Diagnostics, Colorado Springs, CO). Samples were analyzed in duplicates. 
Average post-startle serum cortisol values were calculated from BC3 samples (CortPostAvg). In 
addition, differences in serum cortisol (CortDiff) were calculated by subtracting BC2 values from 
those found in BC3 on the startle test days of each treatment. Intra-assay precision averaged an 
11.36% coefficient of variation. The ELISA plate that each sample was run on (CortPretestPlate 
or CortPosttestPlate) were considered as potential significant predictor variables for CortPostAvg 
and CortDiff models. 
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A subset of samples (from horses in Group 1) were analyzed for serum amino acid content 
via gas chromatography using the procedures described by Zhang et al. (2005). This was done in 
order to verify treatment effect and to compare values with those found in previous studies. 
Concentrations (mmol/L) of serum free tryptophan (Trp), isoleucine, leucine, tyrosine, 
phenylalanine, and valine were obtained from pre- and post-supplementation blood draws (BC1 
and BC2, respectively) on Day 1 and Day 3 of treatment. Difference in serum free tryptophan 
(TrpDiff) was calculated by subtracting values in BC1 from those found in BC2. Additionally, the 
ratio of tryptophan to other large neutral amino acids (Trp:LNAA) was calculated for BC1 and 
BC2 samples. The difference between the ratio seen in BC1 and BC2 (TrpDiff) was considered as 
another response variable.  
Statistical Analysis  
All analyses were carried out using SAS (version 9.4, SAS Inst. Inc., Cary, NC). 
Significance was set at p ≤ 0.05 while trends were identified at p ≤ 0.10. 
Day 1 and Day 3 data were analyzed separately. Correlations were run to identify potential 
covariates for each response variable (ExitSpeed, HR30, HR_Diff, TimetoBL, GluDiff, 
GluPostAvg, LactDiff, LactPostAvg, CortDiff, and CortPostAvg) using PROC CORR. Potential 
covariates included the following: Group (1-3); TimeLag, which was the time (in minutes) from 
tryptophan supplementation until the behavior test was performed; TrtNum, which was the 
sequence (1-4) of treatments; as well as Temperature (°C) and WindSpeed (m/s) outside when 
each behavior test was performed. Correlations between these variables and the response variables 
were examined; a covariate was included in the models for both Day 1 and Day 3 if a significant 
correlation to the response variable was found on either day, as long as significance was maintained 
once added to the model. Additional covariates (GluRunDate, LactRunDate, CortPretestPlate, and 
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CortPosttestPlate) were considered for response variables requiring lab analysis. ANOVA and 
ANCOVA models were constructed for each response variable using PROC MIXED. In all 
models, Horse and Treatment were identified as class variables. If Group, TrtNum, GluRunDate, 
LactRunDate, CortPretestPlate, or CortPosttestPlate were included in any model, they were also 
categorized as class variables. Additionally, Horse was treated as random effect. Treatment means, 
standard errors, and differences between treatments were determined using the PDIFF option in 
LSMEANS.  
The following models were used to evaluate treatment effect on Day 1 and Day 3:  
ExitSpeed = Group + Temperature + Treatment  
HR30 = TrtNum + Treatment  
HR_Diff = Group + TrtNum + Treatment  
TimetoBL = Temperature + Treatment  
GluDiff = GluRunDate + TimeLag + Treatment  
GluPostAvg = TimeLag + Treatment  
LactDiff = Treatment  
LactPostAvg = Treatment  
CortDiff = Treatment  
CortPostAvg = CortPosttestPlate + Treatment  
The subset of the blood samples (n ≤ 4 samples per treatment, day, and blood collection) 
analyzed for amino acid content was also examined using PROC MIXED. Data points were 
excluded from analysis if they were both (1) outside of the range of serum amino acids found in 
horses based on previous literature and (2) more than three standard deviations away from the 
sample mean. Time between supplementation and BC2 was considered as a covariate but was not 
significant and, therefore, not included in the models. Horse, Treatment, and Day were recognized 
as class variables while Horse and Horse*Treatment were random effects. Day 1 and Day 3 data 
were considered separately using the SLICEBY=DAY statement. Treatment means were 
evaluated using the PDIFF option. Effect of treatment number (to evaluate the effectiveness of 
washout periods) and comparisons between blood collections and days were analyzed in PROC 
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MIXED using the PDIFF option in LSMEANS. In these models, Horse, Treatment, TrtNum, Day, 
and blood collection were class variables while Horse and Horse*Treatment remained random 
effects.  
The following models were used to evaluate serum amino acid content in Group 1:  
TrpDiff = Treatment | Day  
RatioDiff = Treatment | Day  
RESULTS 
 Horses remained healthy throughout the study; all resting heart rate, respiratory rate, body 
temperature, and packed cell volume measurements remained within normal limits. Individual 
horse body weight varied somewhat throughout the study and feed/treatment doses were adjusted 
accordingly. Serum glucose, lactate, cortisol, and amino acid levels are compared to expected 
ranges based on previous literature in Table 2.4. 
Correlations between model covariates and response variables, along with covariate effects 
in the models, are presented in Table 2.5. Means and standard deviations for each response variable 
by treatment and day are displayed in Table 2.6.  
LOW 
While heart rate was elevated above baseline at 30 seconds post-startle for both the low 
dose and control on Day 1, heart rate difference was less on Day 1 of the low treatment compared 
to Day 1 of control (P = 0.05). Day 1 lactate difference was also significantly less on the low dose 
than on control (P = 0.03). On the low dose Day 1, average serum lactate was less post startle test 
compared to values before the startle test. On control Day 1, however, lactate increased after the 
startle test. These results indicate that the low treatment had a sedative effect on Day 1 in terms of 
changes in heart rate and serum lactate levels.  




 Day 1 cortisol difference on the medium treatment was less compared to control (P = 0.01). 
Serum cortisol decreased post-startle test on the medium dose while it increased post-startle on 
control. This seems to indicate that the medium treatment had a sedative effect on cortisol levels 
on Day 1. 
 Time for heart rate to return to baseline post-startle was greater on Day 3 of medium dose 
than control (P = 0.03). These results show that the medium dose had an excitatory effect on heart 
rate on Day 3. 
HIGH 
 Cortisol difference before and after the startle test tended to be different on Day 1 of the 
high dose compared to control (P = 0.10). Numerically, serum cortisol levels were lower post-
startle than pre-startle on high treatment Day 1 where levels actually increased after the startle test 
on control Day 1. This trend implies that the high dose may have had a sedative effect on cortisol 
levels on Day 1. 
 Post-startle serum lactate on Day 3 of the high dose showed a trend of being higher than 
on Day 3 of control (P = 0.10), suggesting somewhat of an excitatory effect on this response 
variable. 
Amino Acids 
Mean differences in serum free tryptophan and Trp:LNAA by treatment and day are 
presented in Figures 2.2 and 2.3, respectively. Significance for pairwise comparisons of means 
between treatments are shown in Tables 2.7 and 2.8.  
On Day 1, serum Trp and Trp:LNAA in BC1 did differ significantly from levels in BC2 (P 
< 0.0001 and P < 0.0001, respectively). However, on Day 3, neither Trp nor Trp:LNAA differed 
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significantly from BC1 to BC2 (P = 0.98 and P = 0.99, respectively). In addition, Trp and 
Trp:LNAA on Day 3 BC1 were not significantly different from those seen on Day 1 BC2 (P = 
0.93 and P = 0.87, respectively).  
The efficacy of the washout periods was analyzed by comparing Trp and TRP:LNAA in 
BC1 on Day 1 of each treatment. Treatment number was not significant for serum Trp levels (P = 
0.54) or Trp:LNAA (P = 0.37). 
DISCUSSION 
 We did see serum cortisol levels higher than those previously reported in horses. Serum 
free tryptophan was also seen at higher concentrations than those previously reported but we 
provided oral tryptophan supplement to horses at doses that have not been previously evaluated. 
 It is interesting to note that on Day 1, all treatments had some sort of sedative effect on at 
least one of the response variables whereas on Day 3, either no effect was seen (LOW) or some 
sort of excitatory effect was seen (MED, HIGH) on one of the response variables. The reason for 
this cannot be determined based on this experiment, but one possibility is that horses started to 
experience symptoms of serotonin syndrome and became more excitable on Day 3 at the MED 
and HIGH doses. However, we did not see any of the symptoms of the syndrome as they present 
in other species (Boyer and Shannon, 2005; Gillman, 1999). 
Another potential explanation for the results on Day 3 conflicting with those seen on Day 
1 could be that it is the actual change in the Trp:LNAA ratio that produces the desired sedative 
behavioral effects noted in other species. Some evidence for this may lie in the serum amino acid 
analysis of Group 1 horses, as treatment on Day 3 had little effect on serum free tryptophan 
concentration or Trp:LNAA. The lack of significant changes in amino acid profiles on Day 3 and 
from Day 1 to Day 3 may provide reasoning as to why no significant calming effects were seen in 
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any of the response variables on Day 3. It is possible that serum amino acids would have dropped 
between the time of BC1 and BC2 on Day 3, had the horses not received another treatment during 
that time. Again, we are unsure as to why this is; without further amino acid analysis, we do not 
know how long free tryptophan or Trp:LNAA remain elevated in the serum. We can see that after 
the four-day washout period, levels returned to baseline and treatment number had no significant 
effect. 
 We were surprised at how little significance treatment had on most of the response 
variables and how trends did not seem to be reliable between treatments or days. One exception 
can be seen in the decrease in serum cortisol post-startle on Day 1 of the MED and HIGH 
treatments. These results agree with the response Koopmans et al. (2005) saw in swine 
supplemented with tryptophan; although no behavioral effects were seen in that study, tryptophan 
supplementation reduced plasma cortisol and noradrenaline in pigs exposed to social stress. 
There was a lot of variability among individual horses used in this study. Perhaps testing a 
more homogenous group of horses (in which individuals were of the same breed, sex, and similar 
age) would generate more clear results. Previous research provides evidence that there are 
differences in male and female serotonergic systems and responses to changes in dietary 
Trp:LNAA (Albonetti et al., 1994; Dickinson and Curzon, 1986; Henry et al., 1992; Henry et al., 
1996; Kennett et al., 1986; Kim and Camilleri, 2000; Rouvinen et al., 1999). Alberghina et al. 
(2014) as well as Ferlazzo et al. (2012) saw differences in serum tryptophan in horses of different 
ages. Other studies have observed breed differences (Alberghina et al., 2014; Bagshaw et al., 1994; 
Grimmett and Sillence, 2005). While all of these factors may play a role in the permeability of the 
blood-brain barrier the effectiveness of supplemental tryptophan on serotonin biosynthesis, it is 
also worth considering that these types of treatments may be most effective in horses with 
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dysfunctioning serotonergic systems. This would be in line with research in other species, where 
tryptophan supplements and proserotonergic drugs were most effective in individuals that 
exhibited symptoms of disorder within the serotonin system (Argyropoulos et al., 2004; Bell et al., 
2001; Weld et al., 1998). 
 The environment was another source of variability. Although researchers aimed to keep 
the timing of the tests and the footing within the test chute as consistent as possible, variations in 
temperature, wind, precipitation, and on-farm activities provided uncontrolled stimuli that may 
have impacted the results of the behavior tests. Performing these tests in a more controlled 
environment would be desirable and may provide more reliable results.  
 Including a positive control, with a sedative known to be effective in horses (such as 
acepromazine), may have helped elucidate treatment effects. It’s possible that the startling stimuli 
were too effective at spooking the horses in this experiment and that any treatment effects were 
nullified as a result. Comparing treatment effects to that of a positive control could provide support 
or evidence against this hypothesis.  
 Supplementing tryptophan to horses at higher doses (40 mg/kg BW and 60 mg/kg BW) 
may be an effective way to reduce cortisol levels in stressful situations. We also saw some evidence 
of calming effects of tryptophan at a lower dose (20 mg/kg BW). However, these findings were 
seen in only a few of the results variables measured in this experiment. The horses we used 
responded to tryptophan supplementation more favorably on the first day they received the 
supplement. This finding does not support the directions found on some commercially available 
products that recommend providing the supplement to the horse 24 hours in advance and again 
several hours before a stressful event takes place. The subset of blood samples we analyzed for 
amino acid content provides evidence to refute this recommendation as well. We saw no additional 
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beneficial effects in terms of increasing serum free tryptophan levels or the ratio of tryptophan to 
other large neutral amino acids on Day 3 of supplementation versus Day 1. This experiment 
confirms that supplementing horses with tryptophan is effective at increasing serum free 
tryptophan and the ratio of tryptophan to certain amino acids. We found little evidence for the 
behavioral or physiological calmative effects of supplemental tryptophan in horses at the doses 
tested. However, from the results presented and discussed in this paper, it appears that 
supplementing horses with tryptophan may produce desired results only a few hours after 
administration and that longer term use may provide no additional benefit or may even have 
unwanted effects. 
 When evaluating the use of calming supplements or drugs, it’s important to consider the 
welfare of the horse. While these compounds may be beneficial in alleviating short-term stress and 
anxiety (for example, when veterinary care needs to be provided) the cause of such emotions 
should be evaluated. Horses kept in unnatural environments, managed poorly, or asked to perform 
beyond their level of training may show signs of stress and anxiety. Chronic health issues such as 
ulcers or lameness may also be the culprit. Oftentimes, sedative drugs and supplements are utilized 
to limit unwanted behaviors such as spooking, bolting, rearing, or bucking. Looking into the 
potential causes of unwanted behaviors should be the first step before owners turn to calming drugs 
or supplements. Providing more training, turnout time, or treatment for an underlying disease or 
condition could result in a more sustainable way to reduce a horse’s unwanted behaviors and could 





TABLE 2.1: Horse profile by group 
  n  
Mean 






BCS (1-9)  
Mean 












Group 1  4  6.5  463.0  4.4  152.8  0:4  3:1 
Group 2  3  8.6  493.9  5.7  160.3  0:3  0:3 




TABLE 2.2: Variance between horses 
 
  Day 1   Day 3 
Response Variable Estimate Standard Error Ratio  
(horse : residual)   Estimate Standard Error 
Ratio  
(horse : residual) 
ExitSpeed  
(m/s) 0.953 0.5521 1.773   0.04921 0.2089 0.03719 
HR30  
(bpm) 215.49 131.02 0.7418   208.61 144.05 0.5164 
HR_Diff  
(bpm) 190.12 131.37 0.7159   34.1998 81.1269 0.07998 
TimetoBL  
(sec) 732.31 1142.78 0.1449   7143.96 4253.96 0.8022 
GluDiff  
(mg/dL) 8.6686 7.4146 0.4094   0 . 0 
GluPostAvg  
(mg/dL) 0 . 0   2.0242 9.4039 0.03188 
LactDiff  
(mmol/L) 0.0113 0.01392 0.1805   0.01986 0.01978 0.2628 
LactPostAvg 
(mmol/L) 0.02363 0.01927 0.4152   0.02802 0.02414 0.3843 
CortDiff  
(!g/dL) 0 . 0   1.046 3.3003 0.06633 
CortPostAvg  





TABLE 2.3: Guaranteed analysis of feedstuffs on as-fed basis 
 
Hay: 
Timothy Brome Mix  
Concentrate: 
Purina Equine Senior 
Digestible Energy (Mcal/kg) 2.07  2.70 
Dry Matter (%) 92.3  90.0 
Crude Protein (%) 6.70  min 14 
Estimated Lysine (%) 0.23  min 0.70 
Acid Detergent Fiber (%) 33.5  * 
Neutral Detergent Fiber (%) 55.5  * 
Starch (%) 0.2  max 12 
Crude Fat (%) 2.2  min 5.5 
Ash (%) 4.9  * 
Calcium (%) 0.41  0.5-1.00 
Phosphorus (%) 0.17  min 0.4 
Magnesium (%) 0.17  0.33 
Potassium (%) 1.12  min 1.60 
Sodium (%) 0.03  min 0.24 
Iron (ppm) 64  min 220 
Zinc (ppm) 14  min 220 
Copper (ppm) 4  min 55 








TABLE 2.4: Daily procedures 
 
Day Group A Group B Group C 
1 




Heart rate, temperature, null reactivity 
test 




Heart rate, temperature, weigh, null 
reactivity test 




Heart rate, temperature, null reactivity 
test 




Heart rate, temperature, weigh, null 
reactivity test 
Heart rate, temperature, null reactivity 
test 
Heart rate, temperature, weigh, null 
reactivity test 
6 
Heart rate, temperature, null reactivity 
test 
Heart rate, temperature, weigh, null 
reactivity test 
Heart rate, temperature, null reactivity 
test 
7 
Heart rate, temperature, BC1 (PCV, 
TRP:LNAA), weigh, BC2 (AA, glucose, 
lactate, cortisol), null reactivity test, BC3 
(glucose, lactate, cortisol) 
Heart rate, temperature, null reactivity 
test 
Heart rate, temperature, weigh, null 
reactivity test 
8 
BC1 (PCV, AA), weigh, begin first* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Heart rate, temperature, BC1 (PCV, 
TRP:LNAA), weigh, BC2 (AA, glucose, 
lactate, cortisol), null reactivity test, BC3 
(glucose, lactate, cortisol) 
Heart rate, temperature, null reactivity 
test 
9 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
BC1 (PCV, AA), weigh, begin first* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 





BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
Heart rate, temperature, null reactivity 
test 
11 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
Heart rate, temperature, BC1 (PCV, 
TRP:LNAA), weigh, BC2 (AA, glucose, 
lactate, cortisol), null reactivity test, BC3 
(glucose, lactate, cortisol) 
12 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), weigh, begin first* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
13 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
14 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
15 
BC1 (PCV, AA), weigh, begin second* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
16 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
BC1 (PCV, AA), weigh, begin second* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Washout day: heart rate, temperature, 




BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
18 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
19 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), weigh, begin second* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
20 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
21 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
22 
BC1 (PCV, AA), weigh, begin third* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 




BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
BC1 (PCV, AA), weigh, begin third* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
24 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
25 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
26 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), weigh, begin third* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 





Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
28 
Washout day: heart rate, temperature, 
baseline blood draw (PCV), weigh, null 
reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
29 
BC1 (PCV, AA), weigh, begin fourth* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
30 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
BC1 (PCV, AA), weigh, begin fourth* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
Washout day: heart rate, temperature, 




BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA), null reactivity 
test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
32 
Washout day: heart rate, temperature, 
baseline blood draw (PCV), null 
reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
33 
Washout day: heart rate, temperature, 
baseline blood draw (PCV), null 
reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), weigh, begin fourth* 
treatment, heart rate, temperature, BC2 
(AA, glucose, lactate, cortisol), startle 
reactivity test, BC3 (glucose, lactate, 
cortisol) 
34 
Washout day: heart rate, temperature, 
baseline blood draw (PCV), null 
reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 





Washout day: heart rate, temperature, 
baseline blood draw (PCV), weigh, null 
reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
BC1 (PCV, AA), treatment, heart rate, 
temperature, BC2 (AA, glucose, lactate, 
cortisol), startle reactivity test, BC3 
(glucose, lactate, cortisol) 
36  
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
37   
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
38   
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
39   
Washout day: heart rate, temperature, 
BC1 (PCV), null reactivity test 
 
*Fixed treatments (CON, LOW, MED, HIGH) were assigned in a random order so that no horses within a group were receiving the 





TABLE 2.5: Serum values in horses 
Compound  Ranges found in previous literature  Ranges found in current study 
Glucose (mg/dL)  62
1
 - 134
1  67.5 - 112.5 
Lactate (mmol/L)  0.56
2
 - 2.32
3  0.47 - 2.78 
Cortisol (!g/dL)  0.08
4
 - 25.5
4  0.02 - 56.81 
Free tryptophan (!mol/L)  8.0
5
 - 118.1
6  19.3 - 142.3 
Isoleucine (!mol/L)  36.1
5
 - 171.8
5  72.3 - 120.1 
Leucine (!mol/L)  60.1
6
 - 371.3
5  122.4 - 148.2 
Valine (!mol/L)  115.0
5
 - 311.8
5  164.1 - 201.3 
Penylalanine (!mol/L)  14.7
6
 - 103.4
6  31.1 - 57.3 
Tyrosine (!mol/L)  22.1
6
 - 125.4













1Kahn and Line, 2010 
2Stull and Rodiek, 2000 
3Nogueira et al., 2002 
4Alenka et al., 2008 
5Assenza et al., 2004 












Response Variable Covariate in Model
DAY 1 DAY 3
r* P** estimate ± SE*** r* P** estimate ± SE***
ExitSpeed (m/s)
Group -0.42097 0.0068 -0.44902 0.0022
Temperature (°C) 0.54964 0.0002 0.080 ± 0.017 0.11043 0.4755 0.002 ± 0.029
HR30 (bpm)
TrtNum 0.03286 0.8363 0.31953 0.0391
HR_Diff (bpm)
Group -0.31893 0.0395 -0.42359 0.0052
TrtNum 0.12101 0.4452 0.42941 0.0045
TimetoBL (sec)
Temperature (°C) 0.39175 0.0136 4.114 ± 1.586 0.46337 0.0023 10.950 ± 2.523
GluDiff (mg/dL)
GluRunDate -0.06339 0.7014 -0.38298 0.0161
TimeLag (sec) -0.43873 0.0052 -0.048 ± 0.032 -0.42515 0.0070 -0.105 ± 0.032
GluPostAvg (mg/dL)
TimeLag (sec) -0.38014 0.0142 -0.074 ± 0.029 -0.39329 0.0110 -0.106 ± 0.044
CortPostAvg (!g/dL)
CortPosttestPlate 0.13747 0.3914 0.31034 0.0483
*PROC$CORR:$Pearson$correlation$coefficient*PROC CORR: Pearson correlation coefficient 
**PROC CORR: Prob > |r| under H0: Rho=0 









CON LOW MED HIGH
Response Variable Day 1 Day 3 Day 1 Day 3 Day 1 Day 3 Day 1 Day 3
ExitSpeed (m/s) 5.09 ± 0.38 5.19 ± 0.36 4.77 ± 0.38 5.54 ± 0.36 5.16 ± 0.37 5.12 ± 0.36 5.44 ± 0.39 5.59 ± 0.35
HR30 (bpm) 102.83 ± 6.79 108.36 ± 7.48 97.60 ± 7.05 103.66 ± 7.48 104.04 ± 7.06 99.91 ± 7.80 109.78 ± 6.80 99.02 ± 7.80
HR_Diff (bpm) 69.95 ± 6.48 71.87 ± 6.52 55.33 ± 6.72 68.56 ± 6.53 68.79 ± 6.77 68.19 ± 6.94 74.51 ± 6.48 65.29 ± 6.94
TimetoBL (sec) 224.00 ± 24.15 228.69 ± 38.21 213.53 ± 25.51 224.28 ± 39.69 249.62 ± 24.14 325.88 ± 39.58 209.59 ± 24.19 247.11 ± 39.67
GluDiff (mg/dL) -4.34 ± 1.96 -1.78 ± 1.74 -8.27 ± 1.97 1.79 ± 1.69 -4.96 ± 2.07 1.98 ± 1.76 -0.64 ± 2.03 0.54 ± 1.90
GluPostAvg (mg/dL) 83.36 ± 2.33 85.17 ± 2.57 81.71 ± 2.20 85.41 ± 2.45 83.89 ± 2.25 86.90 ± 2.44 87.88 ± 2.43 87.00 ± 2.73
LactDiff (mmol/L) 0.17 ± 0.09 0.17 ± 0.10 -0.10 ± 0.09 0.30 ± 0.10 0.21 ± 0.08 0.24 ± 0.10 0.22 ± 0.09 0.19 ± 0.11
LactPostAvg (mmol/L) 1.14 ± 0.09 1.09 ± 0.11 0.98 ± 0.09 1.18 ± 0.10 1.25 ± 0.09 1.25 ± 0.11 1.11 ± 0.09 1.35 ± 0.11
CortDiff (!g/dL) 2.79 ± 1.27 -0.29 ± 1.30 1.09 ± 1.27 0.33 ± 1.24 -1.86 ± 1.22 -0.07 ± 1.30 -0.38 ± 1.34 -0.38 ± 1.38












TABLE 2.8: Differences of least squares means for serum free tryptophan (µmol/L) Group 1 horses 
DAY 1   DAY 3 
Treatment P*   Treatment P* 
CON
a LOW
































n=3. *Difference of Least Squares Means. 
TABLE 2.9: Differences of least squares means for Trp:LNAA Group 1 horses 
DAY 1   DAY 3 
Treatment P*   Treatment P* 
CON
b LOW








































































































Fig. 2.2: Average (± s.d.) difference in serum free tryptophan (µmol/L) for Group 1 horses 









































Fig. 2.3: Average (± s.d.) difference in serum Trp:LNAA for Group 1 horses calculated by 
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Analyze Treatment Effects on Behavioral and Physiological Response Variables on Day 1 
 





proc sort data=AllDay1Data; 





Proc Means data=AllDay1Data nway noprint; 
 class Treatment Day; 
 var ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
 output out=SumStats mean=; 
run; 
 
Proc Transpose data=SumStats out=SumStatsTr (rename=(Col1=Y)); 
 by Treatment Day _TYPE_ _FREQ_; 
run; 
 
Proc sort data=SumStatsTr; 
 by _LABEL_; 
 
*Simple interaction plot for each response variable; 
 
Proc Sgplot ; 
 by _LABEL_; 
 series X=Treatment Y=Y; 
run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with exitspeed; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 





*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with HR_Diff; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with TimetoBL; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with GluDiff; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with GluPostAvg; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with LactDiff; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with LactPostAvg; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 
* with CortDiff; 
*run; 
 
*proc corr data=AllDay1Data plots=scatter; 
* var treatment; 





proc corr data=AllDay1Data plots=scatter; 
 var Age; 
!
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 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var BCS; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var Group; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var TimeLag; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var TrtNum; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var Temperature; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var WindSpeed; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var Breed; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  





proc corr data=AllDay1Data plots=scatter; 
 var GluDiff GluPostAvg; 
 with GluRunDate; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var LactDiff LactPostAvg; 
 with LactRunDate; 
run; 
 
proc corr data=AllDay1Data plots=scatter; 
 var CortDiff CortPostAvg; 





proc means data=AllDay1Data mean std; 
 class treatment; 
 var exitspeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc univariate data=AllDay1Data plots; 
 var ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
title 'Day 1 Exit Speed'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Group Horse; 
 model ExitSpeed=Group Temperature Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 HR 30'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment TrtNum Horse; 
 model HR30=TrtNum Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 





title 'Day 1 HR Difference'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Group TrtNum Horse; 
 model HR_Diff=Group TrtNum Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Time to Return to Baseline'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Horse; 
 model TimetoBL= Temperature Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Glucose Difference'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment GluRunDate Horse; 
 model GluDiff=GluRunDate TimeLag Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Glucose Post-Startle Average'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Horse; 
 model GluPostAvg= TimeLag Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Lactate Difference'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Horse; 
 model LactDiff=Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Lactate Post-Startle Average'; 
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Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Horse; 
 model LactPostAvg=Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Cortisol Difference'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Horse; 
 model CortDiff=Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 1 Cortisol Post-Startle Average'; 
Proc Mixed data=AllDay1Data covtest ratio; 
 class Treatment Horse CortPostTestPlate; 
 model CortPostAvg=CortPosttestPlate Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 









Analyze Treatment Effects on Behavioral and Physiological Response Variables on Day 3 
 





proc sort data=AllDay3Data; 





Proc Means data=AllDay3Data nway noprint; 
 class Treatment Day; 
 var ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
 output out=SumStats mean=; 
run; 
 
Proc Transpose data=SumStats out=SumStatsTr (rename=(Col1=Y)); 
 by Treatment Day _TYPE_ _FREQ_; 
run; 
 
Proc sort data=SumStatsTr; 
 by _LABEL_; 
 
*Simple interaction plot for each response variable; 
 
Proc Sgplot ; 
 by _LABEL_; 
 series X=Treatment Y=Y; 
run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with exitspeed; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 





*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with HR_Diff; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with TimetoBL; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with GluDiff; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with GluPostAvg; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with LactDiff; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with LactPostAvg; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 
* with CortDiff; 
*run; 
 
*proc corr data=AllDay3Data plots=scatter; 
* var treatment; 





proc corr data=AllDay3Data plots=scatter; 
 var Age; 
!
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 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var BCS; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var Group; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var TimeLag; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg TrtNum; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var TrtNum; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg TimeLag; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var Temperature; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var WindSpeed; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var Breed; 
 with ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  





proc corr data=AllDay3Data plots=scatter; 
 var GluDiff GluPostAvg; 
 with GluRunDate; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var LactDiff LactPostAvg; 
 with LactRunDate; 
run; 
 
proc corr data=AllDay3Data plots=scatter; 
 var CortDiff CortPostAvg; 





proc means data=AllDay3Data mean std; 
 class treatment; 
 var exitspeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
proc univariate data=AllDay3Data plots; 
 var ExitSpeed HR30 HR_Diff TimetoBL GluDiff GluPostAvg LactDiff LactPostAvg  
  CortDiff CortPostAvg; 
run; 
 
title 'Day 3 Exit Speed'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Group Horse; 
 model ExitSpeed=Group Temperature Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 HR 30'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment TrtNum Horse; 
 model HR30= TrtNum Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 





title 'Day 3 HR Difference'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Group TrtNum Horse; 
 model HR_Diff=Group TrtNum Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Time to Return to Baseline'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Horse; 
 model TimetoBL= Temperature Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Glucose Difference'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment GluRunDate Horse; 
 model GluDiff=GluRunDate TimeLag Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Glucose Post-Startle Average'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Horse; 
 model GluPostAvg=TimeLag Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Lactate Difference'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Horse; 
 model LactDiff=Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Lactate Post-Startle Average'; 
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Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Horse; 
 model LactPostAvg=Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Cortisol Difference'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Horse; 
 model CortDiff=Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 
 lsmestimate Treatment 3 -1 -1 -1/ divisor=3; 
run; 
 
title 'Day 3 Cortisol Post-Startle Average'; 
Proc Mixed data=AllDay3Data covtest ratio; 
 class Treatment Horse CortPosttestPlate; 
 model CortPostAvg=CortPosttestPlate Treatment/ ddfm=kr solution residual; 
 random Horse; 
 lsmeans Treatment / pdiff; 









Analyze Serum Amino Acids of Group 1 Horses 
 






Proc Means data=Group1 nway; 
 class Treatment Day; 
 var TRP_Diff RatioDiff; 
 output out=SumStatsGroup1 mean= ; 
run; 
Proc Transpose data=SumStatsGroup1 out=SumStatsTrGroup1 (rename=(Col1=Y)); 
 by Treatment Day _TYPE_ _FREQ_; 
run; 
Proc sort data=SumStatsTrGroup1; 
 by _LABEL_; 
  
*Simple interaction plot for each response variable; 
Proc Sgplot; 
 by _LABEL_; 
 series X = Treatment Y = Y / group = Day; 
run; 
 
proc corr data=Group1 plots=scatter; 
 var treatment; 
 with TRP_Diff; 
run; 
 
proc corr data=Group1 plots=scatter; 
 var treatment; 
 with RatioDiff; 
run; 
 
title 'Difference in serum free Trp'; 
Proc Mixed data=Group1; 
class Treatment Day Horse; 
model TRP_Diff =  Treatment|Day / ddfm=kr solution residual ;   
random Horse Horse*Treatment ; 





title 'Difference in TRP:LNAA'; 
Proc Mixed data=Group1; 
class Treatment Day Horse; 
model RatioDiff =  Treatment|Day / ddfm=kr solution residual ;   
random Horse Horse*Treatment ; 
slice Treatment*Day / sliceby = Day pdiff; 
run; 
 
title 'Washout serum free Trp'; 
Proc Mixed data=Group1; 
where Day=1; 
class Treatment TrtNum Day Horse; 
model PreTRP =  TrtNum / ddfm=kr solution residual ;   




title 'Washout serum TRP:LNAA'; 
Proc Mixed data=Group1; 
where Day=1; 
class Treatment TrtNum Day Horse; 
model PreRatio =  TrtNum/ ddfm=kr solution residual ;   




PROC IMPORT OUT=WORK.AABCCompare 
 DATAFILE="/home/britdav/AABCCompare.xlsx" 
            DBMS=XLSX REPLACE; 
            GETNAMES=YES; 
RUN; 
 
Proc Mixed data=AABCCompare; 
class Treatment DBC Horse; 
model TRP = DBC / ddfm=kr solution residual ;   
random Horse Horse*Treatment ; 
lsmeans DBC / pdiff; 
run; 
 
Proc Mixed data=AABCCompare; 
class Treatment DBC Horse; 
model Ratio = DBC / ddfm=kr solution residual ;   
random Horse Horse*Treatment ; 






SAS SUMMARY OUTPUT 
 































































































































































































































































































































































Day 1 Exit Speed
The Mixed Procedure





DF F Value Pr > F
Group 2 8.15 0.59 0.5786
Temperature 1 25.2 21.47 <.0001
Treatment 3 25.3 1.25 0.3125
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 5.0861 0.3789 15 13.42 <.0001
Treatment 20 4.7708 0.3790 15 12.59 <.0001
Treatment 40 5.1639 0.3710 14 13.92 <.0001
Treatment 60 5.4357 0.3903 16.4 13.93 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 0.3153 0.3332 25.3 0.95 0.3530
Treatment 0 40 -0.07785 0.3230 25.2 -0.24 0.8115
Treatment 0 60 -0.3496 0.3479 25.4 -1.01 0.3243
Treatment 20 40 -0.3931 0.3229 25.2 -1.22 0.2347
Treatment 20 60 -0.6649 0.3484 25.4 -1.91 0.0677







Day 3 Exit Speed
The Mixed Procedure





DF F Value Pr > F
Group 2 8.84 4.43 0.0465
Temperature 1 29.3 0.00 0.9452
Treatment 3 29 0.62 0.6048
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 5.1867 0.3550 36.1 14.61 <.0001
Treatment 20 5.5371 0.3556 36.2 15.57 <.0001
Treatment 40 5.1191 0.3559 36.2 14.38 <.0001
Treatment 60 5.6902 0.3541 36.1 16.07 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 -0.3503 0.4905 29 -0.71 0.4808
Treatment 0 40 0.06762 0.4942 29 0.14 0.8921
Treatment 0 60 -0.5034 0.4910 29 -1.03 0.3137
Treatment 20 40 0.4180 0.4953 29 0.84 0.4056
Treatment 20 60 -0.1531 0.4915 29 -0.31 0.7577



































































































































Day 1 HR 30
The Mixed Procedure





DF F Value Pr > F
TrtNum 3 25.5 0.39 0.7613
Treatment 3 25.5 0.89 0.4586
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 102.83 6.7946 25 15.13 <.0001
Treatment 20 97.5991 7.0538 26.6 13.84 <.0001
Treatment 40 104.04 7.0556 26.6 14.75 <.0001
Treatment 60 109.78 6.7957 25 16.15 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 5.2280 7.5524 25.5 0.69 0.4950
Treatment 0 40 -1.2107 7.5530 25.5 -0.16 0.8739
Treatment 0 60 -6.9549 7.2998 25.2 -0.95 0.3497
Treatment 20 40 -6.4388 7.7839 25.8 -0.83 0.4157
Treatment 20 60 -12.1830 7.5089 25.5 -1.62 0.1170







Day 3 HR 30
The Mixed Procedure





DF F Value Pr > F
TrtNum 3 25.4 2.08 0.1283
Treatment 3 25.4 0.46 0.7112
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 108.36 7.4783 27.9 14.49 <.0001
Treatment 20 103.66 7.4811 27.9 13.86 <.0001
Treatment 40 99.9135 7.8013 29.4 12.81 <.0001
Treatment 60 99.0201 7.8013 29.4 12.69 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 4.6956 8.6112 25.1 0.55 0.5904
Treatment 0 40 8.4459 8.9035 25.4 0.95 0.3518
Treatment 0 60 9.3393 8.9035 25.4 1.05 0.3041
Treatment 20 40 3.7502 8.8516 25.4 0.42 0.6754
Treatment 20 60 4.6437 8.8516 25.4 0.52 0.6044






































































































































Day 1 HR Difference
The Mixed Procedure





DF F Value Pr > F
Group 2 8.09 0.89 0.4478
TrtNum 3 25.3 1.17 0.3393
Treatment 3 25.3 2.57 0.0762
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 69.9473 6.4825 20.7 10.79 <.0001
Treatment 20 55.3262 6.7246 22.3 8.23 <.0001
Treatment 40 68.7876 6.7672 22.6 10.16 <.0001
Treatment 60 74.5059 6.4824 20.7 11.49 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 14.6211 7.2251 25.3 2.02 0.0537
Treatment 0 40 1.1597 7.2269 25.3 0.16 0.8738
Treatment 0 60 -4.5586 6.9800 25.1 -0.65 0.5196
Treatment 20 40 -13.4613 7.4537 25.5 -1.81 0.0827
Treatment 20 60 -19.1797 7.1829 25.3 -2.67 0.0131







Day 3 HR Difference
The Mixed Procedure





DF F Value Pr > F
Group 2 8.1 4.93 0.0397
TrtNum 3 25.1 4.03 0.0180
Treatment 3 25.3 0.17 0.9131
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 71.8709 6.5172 31.9 11.03 <.0001
Treatment 20 68.5627 6.5299 31.9 10.50 <.0001
Treatment 40 68.1947 6.9445 32.4 9.82 <.0001
Treatment 60 65.2902 6.9445 32.4 9.40 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 3.3082 8.8597 24.9 0.37 0.7120
Treatment 0 40 3.6762 9.1533 25.3 0.40 0.6913
Treatment 0 60 6.5807 9.1533 25.3 0.72 0.4788
Treatment 20 40 0.3680 9.0990 25.3 0.04 0.9681
Treatment 20 60 3.2725 9.0990 25.3 0.36 0.7221




































































































































Day 1 Time to Return to Baseline
The Mixed Procedure





DF F Value Pr > F
Temperature 1 27.5 6.73 0.0150
Treatment 3 24.4 0.62 0.6060
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 224.00 24.1456 33 9.28 <.0001
Treatment 20 213.53 25.5115 33.4 8.37 <.0001
Treatment 40 249.62 24.1412 33 10.34 <.0001
Treatment 60 209.59 24.1871 33 8.67 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 10.4741 33.2647 25 0.31 0.7555
Treatment 0 40 -25.6135 32.1909 24.4 -0.80 0.4339
Treatment 0 60 14.4093 32.1574 24.2 0.45 0.6581
Treatment 20 40 -36.0875 32.8550 23.7 -1.10 0.2831
Treatment 20 60 3.9353 33.3017 25 0.12 0.9069







Day 3 Time to Return to Baseline
The Mixed Procedure





DF F Value Pr > F
Temperature 1 29.7 18.83 0.0002
Treatment 3 26.9 2.44 0.0858
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 228.69 38.2087 24.2 5.99 <.0001
Treatment 20 224.28 39.6891 25.7 5.65 <.0001
Treatment 40 325.88 39.5782 25.9 8.23 <.0001
Treatment 60 247.11 39.6722 25.7 6.23 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 4.4029 41.6165 26.9 0.11 0.9165
Treatment 0 40 -97.1953 41.6093 26.7 -2.34 0.0273
Treatment 0 60 -18.4206 41.6083 26.9 -0.44 0.6615
Treatment 20 40 -101.60 43.1177 27.3 -2.36 0.0259
Treatment 20 60 -22.8235 42.2024 26.5 -0.54 0.5932




































































































































Day 1 Glucose Difference
The Mixed Procedure





DF F Value Pr > F
GluRunDate 8 20.6 1.36 0.2695
TimeLag 1 24.9 2.30 0.1420
Treatment 3 19 3.81 0.0271
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 -4.3400 1.9570 25.6 -2.22 0.0357
Treatment 20 -8.2701 1.9689 25.2 -4.20 0.0003
Treatment 40 -4.9574 2.0685 25.7 -2.40 0.0241
Treatment 60 -0.6361 2.0332 25.4 -0.31 0.7569
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 3.9301 2.4298 18 1.62 0.1232
Treatment 0 40 0.6174 2.7307 18.8 0.23 0.8236
Treatment 0 60 -3.7039 2.3985 18.7 -1.54 0.1393
Treatment 20 40 -3.3127 2.2771 20 -1.45 0.1613
Treatment 20 60 -7.6340 2.2601 18.1 -3.38 0.0033








Day 3 Glucose Difference
The Mixed Procedure





DF F Value Pr > F
GluRunDate 7 27 2.72 0.0284
TimeLag 1 27 10.59 0.0031
Treatment 3 27 1.17 0.3379
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 -1.7820 1.7395 27 -1.02 0.3147
Treatment 20 1.7944 1.6904 27 1.06 0.2979
Treatment 40 -1.9823 1.7606 27 -1.13 0.2701
Treatment 60 0.5449 1.9034 27 0.29 0.7769
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 -3.5764 2.4067 27 -1.49 0.1489
Treatment 0 40 0.2003 2.4302 27 0.08 0.9349
Treatment 0 60 -2.3269 2.5239 27 -0.92 0.3647
Treatment 20 40 3.7766 2.3988 27 1.57 0.1270
Treatment 20 60 1.2495 2.5131 27 0.50 0.6231






































































































































Day 1 Glucose Post-Startle Average
The Mixed Procedure





DF F Value Pr > F
TimeLag 1 36 6.39 0.0160
Treatment 3 36 1.24 0.3082
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 83.3564 2.3252 36 35.85 <.0001
Treatment 20 81.7106 2.1971 36 37.19 <.0001
Treatment 40 83.8935 2.2518 36 37.26 <.0001
Treatment 60 87.8824 2.4258 36 36.23 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 1.6458 3.1847 36 0.52 0.6085
Treatment 0 40 -0.5371 3.2904 36 -0.16 0.8712
Treatment 0 60 -4.5260 3.3519 36 -1.35 0.1854
Treatment 20 40 -2.1830 3.1678 36 -0.69 0.4952
Treatment 20 60 -6.1718 3.2695 36 -1.89 0.0671







Day 3 Glucose Post-Startle Average
The Mixed Procedure





DF F Value Pr > F
TimeLag 1 34.8 5.86 0.0208
Treatment 3 27.8 0.15 0.9320
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 85.1687 2.5740 35.9 33.09 <.0001
Treatment 20 85.4068 2.4460 35.9 34.92 <.0001
Treatment 40 86.8982 2.4430 35.9 35.57 <.0001
Treatment 60 87.0029 2.7334 36 31.83 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 -0.2381 3.4900 27.5 -0.07 0.9461
Treatment 0 40 -1.7295 3.5024 27.7 -0.49 0.6253
Treatment 0 60 -1.8341 3.7018 28 -0.50 0.6241
Treatment 20 40 -1.4914 3.4089 27 -0.44 0.6652
Treatment 20 60 -1.5960 3.6304 28.5 -0.44 0.6635
































































































































Day 1 Lactate Difference
The Mixed Procedure





DF F Value Pr > F
Treatment 3 26.3 3.25 0.0376
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 0.1661 0.08612 33.2 1.93 0.0623
Treatment 20 -0.09890 0.09090 33.8 -1.09 0.2843
Treatment 40 0.2059 0.08197 32.9 2.51 0.0171
Treatment 60 0.2224 0.09090 33.8 2.45 0.0198
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 0.2650 0.1156 25.9 2.29 0.0302
Treatment 0 40 -0.03972 0.1099 26.2 -0.36 0.7207
Treatment 0 60 -0.05622 0.1156 25.9 -0.49 0.6309
Treatment 20 40 -0.3048 0.1137 26.7 -2.68 0.0124
Treatment 20 60 -0.3213 0.1194 26.5 -2.69 0.0122







Day 3 Lactate Difference
The Mixed Procedure





DF F Value Pr > F
Treatment 3 23.8 0.39 0.7643
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 0.1691 0.1029 29.1 1.64 0.1111
Treatment 20 0.2994 0.1029 29.1 2.91 0.0069
Treatment 40 0.2391 0.1029 29.1 2.32 0.0273
Treatment 60 0.1892 0.1090 29.8 1.74 0.0931
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 -0.1304 0.1313 23.6 -0.99 0.3308
Treatment 0 40 -0.07003 0.1313 23.6 -0.53 0.5988
Treatment 0 60 -0.02012 0.1364 24.1 -0.15 0.8840
Treatment 20 40 0.06036 0.1313 23.6 0.46 0.6500
Treatment 20 60 0.1103 0.1364 24.1 0.81 0.4268








































































































































Day 1 Lactate Post-Startle Average
The Mixed Procedure





DF F Value Pr > F
Treatment 3 26 2.16 0.1167
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 1.1373 0.08949 30 12.71 <.0001
Treatment 20 0.9811 0.08932 30.1 10.98 <.0001
Treatment 40 1.2467 0.08557 28.6 14.57 <.0001
Treatment 60 1.1079 0.09386 31.5 11.80 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 0.1562 0.1083 26.2 1.44 0.1611
Treatment 0 40 -0.1095 0.1050 25.8 -1.04 0.3071
Treatment 0 60 0.02942 0.1104 25.6 0.27 0.7920
Treatment 20 40 -0.2656 0.1049 25.6 -2.53 0.0178
Treatment 20 60 -0.1268 0.1121 26.7 -1.13 0.2683








Day 3 Lactate Post-Startle Average
The Mixed Procedure





DF F Value Pr > F
Treatment 3 23.6 1.35 0.2821
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 1.0895 0.1055 28.9 10.33 <.0001
Treatment 20 1.1771 0.1001 28.1 11.76 <.0001
Treatment 40 1.2497 0.1055 28.9 11.85 <.0001
Treatment 60 1.3487 0.1114 30 12.11 <.0001
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 -0.08764 0.1271 23.8 -0.69 0.4972
Treatment 0 40 -0.1602 0.1292 22.9 -1.24 0.2275
Treatment 0 60 -0.2592 0.1343 23.4 -1.93 0.0659
Treatment 20 40 -0.07256 0.1271 23.8 -0.57 0.5734
Treatment 20 60 -0.1716 0.1323 24.2 -1.30 0.2069









































































































































Day 1 Cortisol Difference
The Mixed Procedure





DF F Value Pr > F
Treatment 3 36 2.53 0.0722
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 2.7915 1.2748 36 2.19 0.0351
Treatment 20 1.0943 1.2748 36 0.86 0.3963
Treatment 40 -1.8590 1.2155 36 -1.53 0.1349
Treatment 60 -0.3771 1.3438 36 -0.28 0.7806
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 1.6972 1.8029 36 0.94 0.3528
Treatment 0 40 4.6504 1.7614 36 2.64 0.0122
Treatment 0 60 3.1686 1.8523 36 1.71 0.0958
Treatment 20 40 2.9533 1.7614 36 1.68 0.1023Effect Treatment Treatment Estimate Error DF t Value Pr > |t|
Treatment 20 60 1.4714 1.8523 36 0.79 0.4322








Day 3 Cortisol Difference
The Mixed Procedure





DF F Value Pr > F
Treatment 3 24.1 0.06 0.9783
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 -0.2864 1.3037 35.6 -0.22 0.8274
Treatment 20 0.3276 1.2364 35.4 0.26 0.7926
Treatment 40 -0.06896 1.3037 35.6 -0.05 0.9581
Treatment 60 -0.3839 1.3820 35.7 -0.28 0.7828
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 -0.6140 1.7430 23.8 -0.35 0.7278
Treatment 0 40 -0.2174 1.7926 24.7 -0.12 0.9045
Treatment 0 60 0.09749 1.8339 23.9 0.05 0.9580
Treatment 20 40 0.3966 1.7430 23.8 0.23 0.8220
Treatment 20 60 0.7115 1.8023 24.7 0.39 0.6964



































































































































Day 1 Cortisol Post-Startle Average
The Mixed Procedure





DF F Value Pr > F
CortPosttestPlate 4 23.5 2.85 0.0465
Treatment 3 23.2 0.28 0.8367
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 12.8127 3.1136 13.2 4.12 0.0012
Treatment 20 11.9544 3.0832 12.7 3.88 0.0020
Treatment 40 11.8746 3.0795 12.7 3.86 0.0021
Treatment 60 13.3511 3.1609 13.9 4.22 0.0009
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 0.8583 1.8025 23.1 0.48 0.6384
Treatment 0 40 0.9381 1.7996 23.1 0.52 0.6071
Treatment 0 60 -0.5384 1.9102 23.3 -0.28 0.7806
Treatment 20 40 0.07982 1.7226 23.1 0.05 0.9634
Treatment 20 60 -1.3967 1.8523 23.2 -0.75 0.4584








Day 3 Cortisol Post-Startle Average
The Mixed Procedure





DF F Value Pr > F
CortPosttestPlate 4 23.4 1.70 0.1835
Treatment 3 22.9 0.96 0.4263
Least Squares Means Estimate
Effect Label Estimate
Standard
Error DF t Value Pr > |t|




Error DF t Value Pr > |t|
Treatment 0 12.6517 2.6176 17.2 4.83 0.0001
Treatment 20 10.5505 2.5295 15.6 4.17 0.0008
Treatment 40 13.5042 2.5504 16 5.29 <.0001
Treatment 60 10.7338 2.7088 19.1 3.96 0.0008
Differences of Least Squares Means
Effect Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Treatment 0 20 2.1013 2.0974 23 1.00 0.3269
Treatment 0 40 -0.8525 2.0856 22.9 -0.41 0.6865
Treatment 0 60 1.9180 2.2207 22.8 0.86 0.3968
Treatment 20 40 -2.9537 2.0272 22.7 -1.46 0.1588
Treatment 20 60 -0.1833 2.2046 23.1 -0.08 0.9345


































































































































SAS SUMMARY OUTPUT 
 







Obs Variable Label N Mean Std Dev Minimum Maximum


























































































































Difference in serum free Trp
The Mixed Procedure





DF F Value Pr > F
Treatment 3 22 17.45 <.0001
Day 1 22 96.09 <.0001






































































DF F Value Pr > F
Day 1 3 22 34.80 <.0001
Simple Differences of Treatment*Day Least Squares Means
Slice Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Day 1 0 20 -42.6583 11.3877 22 -3.75 0.0011
Day 1 0 40 -66.5750 10.5429 22 -6.31 <.0001
Day 1 0 60 -105.30 10.5429 22 -9.99 <.0001
Day 1 20 40 -23.9167 11.3877 22 -2.10 0.0474
Day 1 20 60 -62.6417 11.3877 22 -5.50 <.0001
Day 1 40 60 -38.7250 10.5429 22 -3.67 0.0013






DF F Value Pr > F
Day 3 3 22 0.44 0.7239
Simple Differences of Treatment*Day Least Squares Means
Slice Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Day 3 0 20 -3.9000 10.5429 22 -0.37 0.7150
Day 3 0 40 5.8000 10.5429 22 0.55 0.5878
Day 3 0 60 -6.0000 11.3877 22 -0.53 0.6035
Day 3 20 40 9.7000 10.5429 22 0.92 0.3675
Day 3 20 60 -2.1000 11.3877 22 -0.18 0.8554


















DF F Value Pr > F
Treatment 3 18 9.00 0.0007
Day 1 18 63.61 <.0001







































































DF F Value Pr > F
Day 1 3 18 20.23 <.0001
Simple Differences of Treatment*Day Least Squares Means
Slice Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Day 1 0 20 -0.08739 0.02619 18 -3.34 0.0037
Day 1 0 40 -0.1359 0.02450 18 -5.55 <.0001
Day 1 0 60 -0.1957 0.02619 18 -7.47 <.0001
Day 1 20 40 -0.04850 0.02450 18 -1.98 0.0632
Day 1 20 60 -0.1083 0.02619 18 -4.14 0.0006
Day 1 40 60 -0.05982 0.02450 18 -2.44 0.0252






DF F Value Pr > F
Day 3 3 18 0.51 0.6775
Simple Differences of Treatment*Day Least Squares Means
Slice Treatment Treatment Estimate
Standard
Error DF t Value Pr > |t|
Day 3 0 20 -0.01506 0.02450 18 -0.61 0.5465
Day 3 0 40 0.01300 0.02450 18 0.53 0.6022
Day 3 0 60 -0.00337 0.02928 18 -0.12 0.9097
Day 3 20 40 0.02805 0.02268 18 1.24 0.2320
Day 3 20 60 0.01169 0.02778 18 0.42 0.6789























Washout serum free Trp
The Mixed Procedure
Differences of Least Squares Means
Effect TrtNum TrtNum Estimate
Standard
Error DF t Value Pr > |t|
TrtNum 1 2 -0.4500 2.3466 12 -0.19 0.8511
TrtNum 1 3 0.8500 2.3466 12 0.36 0.7235
TrtNum 1 4 2.8000 2.3466 12 1.19 0.2558
TrtNum 2 3 1.3000 2.3466 12 0.55 0.5898
TrtNum 2 4 3.2500 2.3466 12 1.38 0.1913
TrtNum 3 4 1.9500 2.3466 12 0.83 0.4222
Washout serum TRP:LNAA
The Mixed Procedure
Differences of Least Squares Means
Effect TrtNum TrtNum Estimate
Standard
Error DF t Value Pr > |t|
TrtNum 1 2 -0.00119 0.004447 12 -0.27 0.7938
TrtNum 1 3 0.002036 0.004447 12 0.46 0.6552
TrtNum 1 4 0.006502 0.004447 12 1.46 0.1694
TrtNum 2 3 0.003225 0.004447 12 0.73 0.4823
TrtNum 2 4 0.007690 0.004447 12 1.73 0.1094





Comparisons between days and blood collections 
serum free Trp 
 


















Differences of Least Squares Means
Effect DBC DBC Estimate
Standard
Error DF t Value Pr > |t|
DBC 11 12 -56.2678 7.7451 43.2 -7.26 <.0001
DBC 11 31 -56.9563 7.5829 43.1 -7.51 <.0001
DBC 11 32 -57.1518 7.7451 43.2 -7.38 <.0001
DBC 12 31 -0.6884 7.7451 43.2 -0.09 0.9296
DBC 12 32 -0.8840 7.9101 43.4 -0.11 0.9115
DBC 31 32 -0.1956 7.7451 43.2 -0.03 0.9800
The Mixed Procedure
Differences of Least Squares Means
Effect DBC DBC Estimate
Standard
Error DF t Value Pr > |t|
DBC 11 12 -0.1069 0.01576 40 -6.78 <.0001
DBC 11 31 -0.1094 0.01465 39.2 -7.47 <.0001
DBC 11 32 -0.1091 0.01576 40 -6.93 <.0001
DBC 12 31 -0.00255 0.01576 40 -0.16 0.8720
DBC 12 32 -0.00227 0.01644 39.6 -0.14 0.8911
DBC 31 32 0.000289 0.01576 40 0.02 0.9855
